 
TITLE PAGE: PHASE 3 CLINICAL TRIAL 
 
AN OPEN -LABEL, RANDOMIZED, M ULTI -CENTER , PARALLEL -GROUP 
CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN ’S 
INSULIN GLARGINE  WITH LANTUS® IN TYPE 1 DIABETES M ELLITUS 
PATIENTS : AN EXTENSION STUDY 
 
 
Compound Number :  NA 
Compound Name (if applicable):  Insulin G largine  
US IND Number (if applicable):  IND 105279  
European Clinical Trial Database 
(EudraCT) Number (if applicable):  2015- 004353- 40 
Protocol Number:  MYL -1501D -3003  
Phase:  3 
Sponsor:  Mylan Gmb H  
Thurgauerstrasse 40, 8050 Zürich  
Switzerland  
Status:  Final  
Version:  2.0 
Date  06-May-2016  
 
 
 
This document is property of MYLAN. Information provided herein is strictly confidential and is  available for 
review to investigators, Regulatory Authorities and Ethical Committees/Institutional Review Boards. It is 
intended solely for the guidance of the clinical investigation and may not be disclosed to parties not associated 
with the clinical inv estigation (except where required by applicable law) or used for any purpose without the 
prior written consent of MYLAN. In the event of any actual or suspected breach of this obligation, MYLAN 
must be promptly notified.  
Insulin Glargine 
Final Protocol V 2.0 
PROTOCOL# VERSION 
MYL-1501D- 2.0 
3003 MYL-1501D-3003 
06-May-2016 
APPROVAL SIGNATURES 
PROTOCOL TITLE EFFECTIVE 
DATE 
An Open-label, Randomized, Multi-center , 06-May-2016 
Parallel-Group Clinical Trial Comparing the 
Efficacy and Safely of Mylan's Insulin 
Glargine with Lantus® in Type 1 Diabetes 
Mellitus Patients-An Extension Study. 
1, the undersigned, have read this protocol and confinn that lo lhe besl of my knowledge the 
protocol accurately describes the planned conduct of the study, meets all necessary requirements 
of appropriate Standard Operating Procedures (SOPs) and has been reviewed and endorsed by 
the appropriate persons for Clinical Operations, Clinical Development and Statistics. 
Abhijit Shrikrishna Barve, MD, PhD, MBA 
Head, Clinical Sciences 
Mylan Phannaceuticals, Inc 
Michael Ankersen, PhD, MBA 
Clinical Project Lead -Diabetes 
Mylan Phannaccuticals, Inc :::.~';/,~ •• ~ 1JJP,,,;4-r11~-~Yf.!_~~~:t::L -
Principnl Biostntistician 
Mylan Phannaceuticals, Inc 
MYLAN C0Nr1DENT1AL 
Page2 Date 
'1-mav-J.c(6 J 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 3 
 Document History  
Document  Version Date  Summary of Changes  
MYL -1501D -3003  
Clinical Trial Protocol 1.0, 09-Oct-2015 N/A 
MYL -1501D -3003  
Clinical Trial Protocol 
Amendmen t 2.0, 06-May-2016  • Approval Signatures page:  
Version and effective date are changed . 
Sponsor’s personnel and designations changed (Approval Signatures) . 
• In the section Contact Details For 
Reporting Serious Adverse Events , the 
sentence “Any SAE occurring in a 
subject from consent until 28 days after the last dose of the study drug must be 
reported ” has been replaced with “Any 
SAE occurring in a subject from consent until his/her last study visit/phone visit (scheduled or unscheduled) must be reported” . 
• The Synopsis and section 2.1, the  
wording of the  Primary and the  
Secondary objective  of 
Immunogenicity, were modified for clarity . 
• The Synopsis and sections 3.1 and 9.1, 
number of patients  (from estimated 110 
patient to estimated 138 patients)  and 
sites (from estimated 80 to estimated 
70) were modified.  
• The Synopsis, Schedule of Activities, 
Study Flowch art [Figure 1], Sections 
1.1, 3, 3.1, 6.1, 6.2, table 3 were 
modified to include a dditional treatmen t 
period, weeks 24 -36. 
• The following changes made to the 
Schedule of Activities: 
• Clarification made regarding certain data captured in MYL -GAI-3001 that 
will be reused in MYL -1501D -3003 
(Footnotes #8 and #11).  
• Clarification on informed consent 
made (Footnote #3).  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 4 
 • Clarification made regarding ongoing 
adverse events from MYL -GAI-3001 
(Footnote #8).  
• Clarification made that allergic 
reactions, AEs and SAEs will be captured during the follow up period (Footnote #12).  
• Sections 1.1, Background and 
Rationale.  Explanation and rationale for 
the study design change is provided. 
• Section 5.4 -  Clar ification made 
regarding opened and expired study 
medication . 
• Synopsis and Section 6.2 . To minimize 
missing data, clarification added that patients who have been prematurely withdrawn from treatment will be followed up unt il the 40 week follow -up 
call in c ase consent is provided. 
• Schedule of Activities, Section 7.3, 
Table 4 . Blood collection for 
immunogenicity analysis added at 4, 26, 
28, 32 and 36 weeks . 
• Sections 7.3 and 7.4.10. Details of 
central laboratories for immunogenicity 
and safety analyses modified. 
• Sections 7.3.1 and 7.3.2. Methodology 
for im munogenicity assessments were 
modified. 
• Sections 7.4.1 and 7.4.2. Clarifications 
made regarding medical history and prior and concomitant medications. 
• Section 7.5.4. Clarification made 
regarding dilated ophthalmoscopy/ retinal photography testing.  
• Section 8.3. Clarification made 
regarding the collection period for AEs 
and SAEs; text on reporting for withdrawn patients removed, as this is covered in.  
• Section 9. Modifications made 
throughout the data analys is/statistical 
methods section. 
• Section 9.2.1 . Text regarding primary 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 5 
 endpoint  modified to accommodat e 
addition of treatment period. 
• Section 9.2.2. The primary analysis 
population changed from ITT to 
mITT; descriptive tex t on analysis 
populations added. 
• Section 9.7. The primary efficacy 
analysis changed from non -inferiority 
to equivalence.  
• Investigator Agreement Page added to 
body of protocol ( previously appended 
separately).  
• Minor editorial and formatting corrections made throughout the 
protocol.  
 
                        
     
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 6 
 CONTACT DETAILS FOR REPORTING SERIOUS ADVERSE EVENTS  
A serious adverse event (SAE) is any event which is fatal or life -threatening, requires or 
prolongs hospitalization, is significantly or permanently disabling or incapacitating, constitutes a 
congenital anomaly or birth defect, is medically significant, or  require s medical or surgical 
intervention to prevent one of the se outcomes  (please see section 8.2.4 for a detailed definition) . 
Any SAE occurring in a subject from consent until his/her last study visit/phone -visit (scheduled 
or unscheduled) must be reported.  
The Investigator will ensure that the SAE reporting form is completed and emailed/faxed by the 
Investigator to the Pharmacovigilance department, Mylan , within 24 hours of learning of the 
occurrence of any SAE, even if the SAE does not appear to be drug -related. The original SAE 
reporting form, together with the email/fax confirmation sheet, must be kept with the case report forms at the study site. More details are provided in the protocol. 
 
Pharmacovigilance Department  
Name  Global Product Safety & Risk Management  
Mylan  
Email ID  PV MAIL HUB FOR IMMEDIATE SAFETY REPORTS: 
pvclinical@mylan.com  
Phone number  +1.304.554.6641 for Americas  
+44 (0)1707. 853. 000 for sites outside Americas ( e.g., Europe, 
APAC, South Africa etc.) 
Fax number  +1.304.285.6409  
              
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 7 
 TABLE OF CONTENTS  
Table of Contents  
TITLE PAGE: PHASE 3 CLINICAL TRIAL  ............................................................................................................ 1 
APPROVAL SIGNATURES  ........................................................................................................................................ 2 
CONTACT DETAILS FOR REPORTING SERIOUS ADVERSE EVENTS  ......................................................... 3 
TABLE OF CONTENTS  .............................................................................................................................................. 7 
LIST OF ABBREVIATION S ..................................................................................................................................... 12 
PROTOCOL SYNOPSIS  ............................................................................................................................................ 14 
SCHEDULE OF ACTIVITI ES .................................................................................................................................. 18 
 INTRODUCTION  ...................................................................................................................................... 21 
 Background and Rationale  ............................................................................................................................ 21 
 Clinical data on Lantus® ............................................................................................................................... 23 
 STUDY OBJECTIVES AND  ENDPOINTS  ............................................................................................. 23 
 Objectives  ..................................................................................................................................................... 23 
 STUDY DESIGN  ........................................................................................................................................ 24 
 Study Duration  .............................................................................................................................................. 25 
 Allocation to Treatment  ................................................................................................................................ 25 
 Patient Numbering  ........................................................................................................................................ 25 
 Blinding  ........................................................................................................................................................ 26 
 Breaking the Blind  ........................................................................................................................................ 26 
 PATIENT SELECTION  ............................................................................................................................ 28 
 Inclusion Criteria  .......................................................................................................................................... 28 
 Exclusion Criteria  ......................................................................................................................................... 29 
 STUDY TREATMENTS AND CONCOMITANT MEDICATI ON ...................................................... 29 
 Study Medication  .......................................................................................................................................... 29 
 Mealtime insulin  ........................................................................................................................................... 30 
 Ancillary Supplies  ........................................................................................................................................ 30 
 Drug Storage  ................................................................................................................................................. 31 
 Drug Accountability ..................................................................................................................................... 33 
 Dispensing .................................................................................................................................................... 33 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 8 
 
 Administra tion .............................................................................................................................................. 34 
 Return of Study Drug .................................................................................................................................... 34 
 Treatment Compliance  .................................................................................................................................. 34 
 Concomitant Medication  .............................................................................................................................. 34 
 STUDY PROCEDURES  ............................................................................................................................ 36 
 Visit Schedules and SMBG Profiles  ............................................................................................................. 36 
 Patient Withdrawal  ....................................................................................................................................... 37 
 STU DY ASSESSMENTS AND M ETHODS  ............................................................................................ 38 
 Handling of Blood Samples  .......................................................................................................................... 38 
 Efficacy Assessments  ................................................................................................................................... 38 
7.2.1. HbA1c  .................................................................................................................................................................. 38 
7.2.2. Fasting Plasma Glucose (FPG)  ............................................................................................................................ 38 
7.2.3. Body Weight and BMI ......................................................................................................................................... 38 
7.2.4. 8- point SMBG profiles  ........................................................................................................................................ 39 
7.2.5. Daily Insulin Doses .............................................................................................................................................. 39 
 Immunogenicity Assessments ....................................................................................................................... 39 
7.3.1. Anti -Drug Antibody ............................................................................................................................................. 40 
7.3.2. Antibodies against Host Cell Protein Antibodies (anti -HCP)  .............................................................................. 42 
 Safety Assessments  ....................................................................................................................................... 43 
7.4.1. Medical History  ................................................................................................................................................... 43 
7.4.2.  Prior and Concomitant Medication  ...................................................................................................................... 43 
7.4.3. Vital Signs  ........................................................................................................................................................... 43 
7.4.4. Physical Examination  .......................................................................................................................................... 43 
7.4.5. Electrocardiogram ................................................................................................................................................ 43 
7.4.6. Local and Systemic Allergic Reactions  ............................................................................................................... 44 
7.4.7. Adverse Events and Serious Adverse Events  ...................................................................................................... 44 
7.4.8. Hypoglycemic Events  .......................................................................................................................................... 44 
7.4.9. Safety Related to Device Use .............................................................................................................................. 44 
7.4.10. Safety Laboratory Assessments  ......................................................................................................................... 46 
 Other Assessments  ........................................................................................................................................ 47 
7.5.1. Demographic Variables  ....................................................................................................................................... 47 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 9 
 7.5.2. Pregnancy Test  .................................................................................................................................................... 47 
7.5.3. Study Treatment Non- Compliance  ...................................................................................................................... 47 
7.5.4. Dilated Ophthalmoscopy / retinal photography  ................................................................................................... 48 
7.5.5. Patient Diary  ........................................................................................................................................................ 48 
7.5.6. Hypoglycemia  ...................................................................................................................................................... 48 
 ADVERSE EVENT REPORTING  ........................................................................................................... 51 
 Adverse events  .............................................................................................................................................. 51 
 Definitions  .................................................................................................................................................... 52 
8.2.1.  Adverse Events  .................................................................................................................................................... 52 
8.2.2. Adverse Drug Reaction ........................................................................................................................................ 52 
8.2.3. Unexpected Adverse Event/Adverse Drug Reaction  ........................................................................................... 53 
8.2.4. Serious Adverse Events  ....................................................................................................................................... 53 
 Management of Adverse Events  ................................................................................................................... 55 
8.3.1. Collection ............................................................................................................................................................ 55 
8.3.2. Evaluation ............................................................................................................................................................ 56 
 Special Situations  ......................................................................................................................................... 62 
8.4.1. Pregnancy  ............................................................................................................................................................ 62 
8.4.2. Overdose, Medication Errors and Other Events  .................................................................................................. 63 
 Abnormal Test Findings  ............................................................................................................................... 63 
 DATA ANALYSIS/STATIS TICAL METHODS  ..................................................................................... 64 
 Sample Size Determination  .......................................................................................................................... 64 
 General Considerations  .................................................................................................................................  64 
9.2.1. Primary End Point  ............................................................................................................................................... 65 
9.2.2. Study Population .................................................................................................................................................. 65 
9.2.3. Handling Missing Values  .................................................................................................................................... 65 
9.2.4. Pooling .................................................................................................................................................................  66 
9.2.5. Multipl icity Adjustment ....................................................................................................................................... 66 
9.2.6. Statistical Methods  .............................................................................................................................................. 66 
 Patient Disposition  ........................................................................................................................................ 66 
 Protocol Violation  ......................................................................................................................................... 67 
 Patient Characteristics  .................................................................................................................................. 67 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 10 
 
 Concomitant Medication  .............................................................................................................................. 67 
 Primary Efficacy Analysis  ............................................................................................................................ 67 
 Secondary Efficacy Analyses  ....................................................................................................................... 67 
 Safety Analyses  ............................................................................................................................................ 68 
9.9.1. Treatment Exposure  ............................................................................................................................................. 68 
9.9.2. Immunogenicity Profiles Analyses  ...................................................................................................................... 68 
9.9.3. Hypoglycemia Analyses  ...................................................................................................................................... 69 
9.9.4. Adverse Event Analyses  ...................................................................................................................................... 70 
9.9.5. Vital Signs  ........................................................................................................................................................... 70 
9.9.6. Laboratory Measurement  ..................................................................................................................................... 70 
9.9.7. ECG  ..................................................................................................................................................................... 70 
9.9.8. Device Safety Assessment  ................................................................................................................................... 71 
 Subgroup Analyses  ....................................................................................................................................... 71 
 QUALITY CONTROL AND QUALITY ASSURANCE  ........................................................................ 71 
 Study Monitoring  .......................................................................................................................................... 71 
 Audits and Inspections  .................................................................................................................................. 72 
 DATA HANDLING AND RE CORD KEEPING  ..................................................................................... 72 
 Electronic Case Report Forms  ...................................................................................................................... 72 
 Record Retention  .......................................................................................................................................... 73 
 Data Confidentiality ...................................................................................................................................... 74 
 Source Data Access  ...................................................................................................................................... 74 
 Responsibilities Related to Devices  .............................................................................................................. 74 
11.5.1. Investigator Records and Reports ( See Appendix V -  Letter of Approval of Pen Use by the 
Investigator)  .................................................................................................................................................. 74 
 PROTOCOL AMENDMENTS,  DEVIATIONS AND COMPL IANCE  ................................................ 75 
 ETHICS  ....................................................................................................................................................... 76 
 Institutional Review Board (IRB)/Independent Ethics Committee (IEC) ..................................................... 76 
 Ethical Conduct of the Study  ........................................................................................................................ 77 
 Patient Information and Consent  .................................................................................................................. 77 
 DEFINITION OF END OF  TRIAL  .......................................................................................................... 77 
 End of Trial in a Member State  .................................................................................................................... 78 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 11 
 
 End of Trial in all Other Participating Countries  .......................................................................................... 78 
 SPONSOR DISCONTINUAT ION CRITERIA  ....................................................................................... 78 
 PUBLICATION OF STUDY  RESULTS  .................................................................................................. 79 
 Communication of Study Results  ................................................................................................................. 79 
 Publications by Investigators  ........................................................................................................................ 79 
 REFERENCES  ........................................................................................................................................... 80 
 APPENDICES  ............................................................................................................................................. 82 
Appendix I -  Questionnaire to Assess Hypoglycemia Unawareness  ............................................................................. 83 
Appendix II -  Suggested Guidance for Insulin Dose Titration  ...................................................................................... 84 
Appendix III -  4-Point and/or 8 -Point Glucose Estimation Time Points  ....................................................................... 85 
Appendix IV -  Sample Patient Diary Information  ......................................................................................................... 86 
Appendix V -  Letter of Approval of Pen Use by the Investigator (for US Sites only)  .................................................. 87 
 
TABLES  
Table 1: Humalog Kwikpen Usage Instructions  .............................................................................................. 33 
Table 2: Medications That Are Likely to Interfere with Diabetes Control  ...................................................... 36 
Table 3: SMBG Profile Requirements by Visit  ............................................................................................... 37 
Table 4: Blood Volume Needed for Immunogenicity Analysis  ....................................................................... 39 
Table 5: Central Laboratory Details for Safety Sample Shipment  .................................................................. 46 
Table 6: Clinical Severity of Adverse Events  .................................................................................................. 56 
Table 7: Action Taken for an Adverse Event  .................................................................................................. 57 
Table 8: Definition of Suspected Relationship between the Events and Trial Medication  .............................. 58 
 
FIGURES  
Figure 1: Study Flowchart  ............................................................................................................................... 27 
 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 12 
 LIST OF ABBREVIATIONS  
Abbreviation  Definition  
ADA  American Diabetes Association  
ADR  adverse drug reaction  
AE(s)  adverse event(s)  
ALT  alanine transaminase  
ANCOVA analysis of covariance  
AST  aspartate transaminase  
BMI  body mass index  
CI confidence interval  
CMH  Cochran- Mantel -Haenszel  
CRF  case report form  
DCCT  Diabetes Control and Complications Trial  
DNA  deoxyribonucleic acid  
ECG  Electrocardiogram  
eCRF  electronic case report form  
EOT  end of treatment  
FDA Food and Drug Administration (United States)  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
HbA1c  glycosylated hemoglobin  
HBsAg  hepatitis B surface antigen  
HCP  host cell protein  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
IB Investigator’s brochure  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 13 
 Abbreviation  Definition  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC independent ethics committee  
IRB institutional review board  
ITT Intention to treat  
IU International Unit  
IVRS  interactive voice response system  
IWRS  interactive web response system  
JNC Joint National Committee  
LDL  low density lipoprotein  
LOCF  last observation carried forward  
MDP  manic depressive psychosis  
MedDRA  Medical Dictionary for Regulatory Activities  
NAb  neutralizing antibody  
NPH  neutral protamine Hagedorn 
PD pharmacodynamic(s)  
PK pharmacokinetic(s)  
PP Per protocol  
SAE(s)  serious adverse event(s)  
SD standard deviation  
SMBG  self-monitored blood glucose  
T1DM  type 1 diabetes mellitus  
T2DM  type 2 diabetes mellitus  
WHO World Health Organization  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 14 
 PROTOCOL SYNOPSIS  
Title  An Open -label, Randomized, Multi -center, Parallel -Group Clinical Trial Comparing the Efficacy  
and Safety of Mylan’s Insulin Glargine  with Lantus® in Type 1 Diabetes Mellitus Patients : An 
Extension Study 
Objectives  To compare the following variables when Mylan’s insulin glargine and Lantus® are 
interchanged:  
Primary objective  
• Demonstrate the equivalence of changes in HbA1C between two treatment sequence 
groups  
 
Secondary objective 
• Change in basal insulin dose per unit body weight (U/Kg/day)  
• Immunogenicity: incidence and change from baseline in the relative levels of ADA, 
incidence and change from baseline in the relative levels of anti -HCP antibodies.  
• Rate of hypoglycemic events per 30 days and occurrence of hypoglycemia  
• Occurrence of local reactions, systemic reactions and other adverse events  
• Change in fasting plasma glucose  
• Change in 8 -point SMBG profile  
• Device -related safety assessments  
Proposed 
Number of 
Sites  From approximately 7 0 selected sites, approximately 69 patients will be included in each arm, 
with a target of approximately 138 randomized patients in both arms together.  
Study 
Population  Patients with an established diagnosis of T1DM per ADA 2014 criteria who were randomized to the Lan tus
® treatment arm of the MYL -GAI-3001 study, and who have completed the 52- week 
treatment period on Lantus® will be eligible to be screened for the MYL -1501D -3003 study.   
Duration of Patient 
Participation  The maximum possible duration of patient participation in the extension study is approximately 
40 weeks, which includes:  
1. Randomized comparative treatment period 1: 12 weeks.  
2. Randomized comparative treatment period 2: 12 w eeks.  
3. Randomized comparative treatment period 3 : 12 weeks.  
4. Follow -up period: 4 weeks.  
Study Design  This multi -center, open -label, randomized clinical extension study in patients with T1DM will 
assess interchangeability of Mylan’s insulin glargine and Lantus® with respect to safety and 
efficacy.  
Patients with an established diagnosis of T1DM per ADA 2014 criteria who were randomized to the Lan tus
® treatment arm of the MYL -GAI-3001 study, and who have completed the 52- week 
treatment period on Lantus® will be eligible to be screened for the  MYL -1501D -3003 study.  
There will be 2 treatment arms (with 3  sequences) in the extension study.  
Patients randomized to Lantus® during MYL -GAI-3001 will be randomized to either Lantus® or 
Mylan’s insulin glargine for 12 weeks . After this first 12 weeks of treatment, those on Mylan’s 
insulin glargine will be switched to Lantus® while those on Lantus® will continue on Lantus® for 
another 12 weeks to complete the second treatment period.  After  24 weeks of treatment, those  
patients who were randomized to  Mylan’s insulin glargine  and had a switch  to Lantus® will 
undergo  an additional switch to  Mylan’s insulin glargine  for an additional 12 weeks  to complete 
the third treatment period.  Those patients who are on Lantus® since the start of the study  and did 
not have any switch , will continue  on Lantus® for another 12 weeks to complete the  third 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 15 
 treatment period.  
After 36 weeks of treatment, patients will go back to the approved medications (as prescribed ) 
and will be followed up for safety for another 4 weeks  (Mylan will not provide any medications 
from 36 weeks of treatment onwards) . The 36 to 40 week safety  data will also be captured.  
During the 36- week s treatment period, the titration (if needed) of both Mylan’s insulin glargine 
and Lantus® should be kept to a minimum, unless there are safety concerns.  
The week 52 visit for MYL -GAI-3001 will also serve as the week 0 visit for the extension study.  
Number of 
Patients  From approximately 70 selected sites, approximately 69 patients will be included in each arm, 
with a target of approximately 138 randomized patients in both arms together.  
Inclusion 
Criteria  Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
extension study:  
1. Patients who have completed the 52 -week treatment period  (irrespective of their age at the 
completion of MYL -GAI-3001)  of MYL -GAI-300 and were assigned to Lantus® in MYL -
GAI-3001.   
2. Patients or their legal representatives must give written and signed informed consent before 
starting any protocol -specific procedures.  
3. The patient is able and willing to comply with the requirements of the extension study 
protocol including the 8 -point S MBG, completion of the patient diary records  as per the 
instructions  and following a recommended diet and exercise plan for the entire duration of 
the extension study.  
4. Female patients complying with the following:  
o Female patients of childbearing potential must be using oral contraception or two 
other acceptable methods of contraception (e.g., intra -uterine device plus condom, 
spermicidal gel plus condom, diaphragm plus condom, etc.)  from the time of 
randomization throughout the entire study . 
o Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception.  
o Postmenopausal females must have had no menstrual bleeding for at least 1 year 
prior to inclusion  to MYL -1501D- 3003 .    
o Female patients who report surgical sterilization must have had the procedure at 
least 6 months prior to inclusion  to MYL -1501D- 3003.  
o All female patients of childbearing potential, must have negative pregnancy test 
results at baseline (week 0) and at each clinic visit as per the SCHEDULE OF 
ACTIVITIES . 
o If female patients have male partners who have undergone vasectomy, the 
vasectomy must have occurred more than 6 months prior to inclusion  in MYL -
1501D -3003 . 
Exclusion 
Criteria  Patients meeting any of the following criteria will not be  included in the extension study:  
1) History or presence of a medical condition or disease that in the I nvestigator’s opinion 
would place the patient at an unacceptable risk from trial participation.  
2) History of clinically significant (i.e., significant enough  to alter the insulin dose requirement, 
as per the I nvestigator) acute bacterial, viral or fungal systemic infections in the 4 weeks 
prior to inclusion / randomization (recorded while collecting patient history)  in the MYL -
1501D -3003 extension study . 
3) Patie nts scheduled to receive another investigational drug during the extension study period . 
4) Any major elective surgery requiring hospitalization planned during the extension study 
period.  
5) Moderate insulin resistance, defined as requiring insulin  (Basal + Prandial)  of ≥1.5 U/kg/day 
(Lantus® in U/kg/day or Mylan’s insulin glargine in IU/kg/day ). 
Withdrawal 
Criteria  If, for any reason, a patient discontinues the trial prematurely, the patient may be followed up 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 16 
 upon consent and as  described in the following withdrawal criteria : 
Following are the withdrawal criteria:  
1. Withdrawal of consent.  
2. For female patie nts, diagnosis of pregnancy or stated intention to become pregnant. Effort 
should be made so that the pregnant women still repor t to the site and are followed until 
delivery or termination.  
3. Repeated protocol non -compliance.  
4. At the investigator’s discretion , (following discussion with the sponsor medical monitor), 
for safety issues such as severe hypoglycemia or hypoglycemic unawar eness. The site 
should follow -up these patients as  per the SCHEDULE OF ACTIVITIES  until the 40 week 
follow -up call.  
5. At the investigator’s discretion , (following discussion with the sponsor medical monitor), 
in certain situations such as significant intercurrent illness, hospitalization for surge ry, or 
an SAE . The site should follow -up these patients as  per the  SCHEDULE OF ACTIVITIES  
until the 40 week follow -up call . 
Study 
Treatments  Investigational Products  
• Mylan’s insulin glargine  (test product)  100 IU/mL  
• Lantus® from Sanofi -Aventis sourced from the US ( US listed drug ) 100 U/mL  
Both investigational products will be provided in a pre -filled disposable pen with a 3  mL 
cartridge.  
Mealtime  insulin  
• Humalog® (insulin lispro injection, 100 U/mL), manufactured by Eli Lilly (administered in 
Humalog Kwikpen® disposable pens).   
All patients will continue on insulin lispro for the complete trial. The I nvestigator will inform the 
patients of the doses to be used and the titration scheme to be followed  (if needed during the 
study) . During the trial period dose titration  (if needed)  will be kept to a minimum.  
Concomitant 
Medications 
and Therapy  Other than study drugs, insulin , insulin analogs and other anti -diabetes medications  as well as 
glucocorticoid therapy  (oral, intravenous , inhaled  or other route s that produce  systemic effects ) 
should not be taken during the study ( prohibited medications) .  
A list of restricted medications that may interfere with the effect of insulin is given in the below 
table. No drugs listed in this table should  be started during the treatment period.  
All treatments being taken by the patients following signing the ICF  in addition to the trial 
treatment (investigational products and mealtime insulin) during the trial are regarded as 
concomitant medications and must be documented in the CRF.  Mylan’s insulin glargine, 
Lantus® and insulin lispro  will not be considered as concomitant medications.  
 
Drug classes that are known to augment  the 
blood glucose lowering effect of insulin such 
as: Drugs and drug classes that are known to 
decrease the blood glucose lowering effect of 
insulin such as : 
1. salicylates at doses more than  
>2 g/day 
2. sulfa antibiotics  
3. angiotensin converting enzyme 
inhibitors  
4. disopyramide  
5. fibrates  
6. fluoxetine  
7. monoamine oxidase inhibitors  1. danazol  
2. niacin  
3. diuretics  
4. sympathomimetic agents  
5. glucagon  
6. isoniazid  
7. somatropin  
8. thyroid hormones  
9. oral contraceptives  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V 2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 17 
 8. propoxyphene  
9. pentoxifylline  
10. somatostatin analogs  
11. bromergocryptine (bromocryptine)  
12. anabolic steroids.  10. estrogens  
11. progestogens  
12. protease inhibitors  
13. phenothiazine derivatives  
14. atypical antipsychotic medications 
(e.g. olanzapine and clozapine).  
 
 
Insulin Glargi ne  MYL -1501D -3003  
Final Protocol  V2.0    06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 18 
 SCHEDULE OF ACTIVITI ES 
     Visits 
 V1 V2 V3 V4 V5 V6 V7 V8  
V9  
V10  
V11  
V12 V131 
(EOT)  V142 
(FU) 
  Extension Study  Week 0 2 4 8 12 14 16 20 24 26 28 32 36 40 
                                                            Extension Study Day  0 14±3  28±3  56±3  84±3  98±7  112±7  140±7  168±7  182±7  196±7  224±7  252±7  280±7  
Informed Consent3 x              
Inclusion/Exclusion Criteria R eview x              
Previous and current i nsulin usage history  √              
Dilat ed Ophthalmoscopy / Retinal photography testing4  x x x            
Standard-of-care specifics5 x x x x x x x x x x x x x  
Age, Gender, Race x              
Body Weight, Height and BMI11 √            x  
Pregnancy Test6 √ x x x x x x x x x x x x  
Medical History and C oncomitant Illness  x              
Concomitant Medications x x x x x x x x x x x x x  
Vitals signs measurement (sitting) √ x x x x x x x x x x x x  
Physical examination √ x   x x   x x   x  
12-lead ECG  (supine) √    x x   x x   x  
Fresh Randomization with capture of old randomization number7 x              
Record AEs and SAEs, local and systemic allergic reactions and 
hypoglycemic events8  x x x x x x x x x x x x x  
x12 
Record device safety information (disposable needle or pen)   x x x x x x x x x x x x  
Fasting Plasma Glucose √   x x   x x    x  
HbA1c Assay √    x    x    x  
HIV, HBsAg, and HCVAb √              
Sampling for hematology, blood chemistry and urinalysis9 √    x    x    x  
Fasting lipid profile √    x    x    x  
Sampling for immunogenicity  √ x x x x x x x x x x x x  
Review 8 -point SMBG Profile performed in the week before the 
visit 10 √ x x x x x x x x x x x x  
Dose review of Mylan’s insulin glargine/Lantus® and insulin 
lispro and instruction  x x x x x x x x x x x x   
Dispense Trial  Medication and ancillary s upplies x  x x x  x x x  x x   
Insulin Glargi ne  MYL -1501D -3003  
Final Protocol  V2.0    06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 19 
      Visits 
 V1 V2 V3 V4 V5 V6 V7 V8  
V9  
V10  
V11  
V12 V131 
(EOT)  V142 
(FU) 
  Extension Study  Week 0 2 4 8 12 14 16 20 24 26 28 32 36 40 
                                                            Extension Study Day  0 14±3  28±3  56±3  84±3  98±7  112±7  140±7  168±7  182±7  196±7  224±7  252±7  280±7  
Drug Accountability and Compliance  x x x x x x x x x x x x  
Dispense patient diary x x x x x x x x x x x x   
Review patient diary  x x x x x x x x x x x x  
1. At the EOT the Investigator will discuss with the patient the prescription medication that the patient should take after the end of the extension study, and provide dosing instructions . 
(Mylan will not provide any medications from 36 weeks of treatment onwards)  
2. Follow -up visit  will be a t elephon e contact.  
3. Informed consent should be signed on the Day “0” prior to initiating any study related activities   
4. Dilated Ophthalmoscopy / Retinal photography testing should be performed once  within  one of the visits during the  28 days of enrolment  
5. Standard –of-care specifics includes assessment and documentation of the following - Traini ng on self -management of diabetes, lifestyle modification measures (includes maintenance of 
appropriate body weight, following recommended physical activity, avoidance of smoking and following the recommended diet); a nd monitoring to prevent complications.  
6. Urine  pregnancy  test will be conducted  at specified visits. Re sults of the pregnancy test should be confirmed as negative before dispensing trial drug(s).  
7. The MYL -GAI-3001 randomization number should also be captured during the new randomization along with the new randomization numbers .  
8. Hypoglycemia that had occurred before MYL -1501D -3003 week 0 visit will be noted in source document and will be used for comparisons. . Ongoing adverse events from MYL -GAI-
3001 will be recorded as adverse events . 
9. A routine urine dipstick will be performed by the site. A urinalysis by microscopic urinalysis may be performed by the centra l lab if the dipstick result is abnormal, and if requested by 
the Investigator.   
10. The 8-point SMBG profile measurement needs to be d one by the patient at home on any 3 days (of which 2 days should be consecutive) in the week of  the visit (i.e. during the 7 days 
before the day of the visit) . 
11. Only body weight will be measured at EOT visit.  Height at V1  of MYL -GAI-3001 will be used to calculate BMI . 
12. Allergic reactions , AEs and SAEs will be captured . 
‘√’ represents information already collected in the MYL -GAI -3001  trial. T he same information should be used in this extension study.  
‘x’ represents new information to be  collected in the extension study.  
AE: adverse event; BMI: body mass index; ECG: electrocardiogram; EOT: end of treatment; HbA1c: glycosylated hemoglobin; HBsAg : hepatitis B surface antigen; HCVAb: hepatitis C 
virus antibody; HIV: Human Immunodeficiency Vi rus; SAE: serious adverse event; SMBG: self -monitored blood glucose.  
Hematology panel will include hemoglobin, hematocrit, white blood cell count with differentials, red blood cell count with indices (mean corpuscula r volume, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration) and platelet count.  
Blood chemistry panel will include blood urea / BUN, serum creatinine, creatinine kinase, uric acid, serum bilirubin (total and direct), total protein, serum albumin, ALT, AST, alkaline 
phosphatase, LDH, lipase, sodium, potassium, calcium, magnesium, chloride, and bicarbonate.  
For the urinalysis a routine urine dip will be performed by the site, using supplies provided by the central laboratory. This  will include assessment of specific gravity , pH, and semi -
quantitative "dipstick" evaluation of glucose, protein, bilirubin, ketones, leukocytes  and blood. If the i nvestigators want to do detailed urine testing, the site will send a urine sample to the 
central laboratory for microscopic evaluation.  Microscopic examination will include WBC, RBC, casts, cast type, crystals, epithelial cells, renal cells, mucus threads, bact eria, yeast, and 
Trichomonas)  
Physical examination activities  will include the following assessments: general appearance, head, ears, eyes, nose and throat (including thyroid), skin, respiratory system, cardiovascular 
Insulin Glargi ne  MYL -1501D -3003  
Final Protocol  V2.0    06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 20 
 system, abdomen, lymph nodes, musculoskeletal system, gastrointestinal system (including mouth) and neurological system; and a diabetic foot examination  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 21 
 
 INTRODUCTION 
Insulin secretion in healthy subjects is characterized by relatively constant basal insulin 
secretion with a post -prandial surge. Type 1 diabetes mellitus (T1DM) is characterized by 
loss of the insulin- producing beta -cells of the islets of Langerhans in th e pancreas, leading to 
a deficiency of insulin. The primary cause of beta -cell loss is a T -cell mediated autoimmune 
attack [ 1]. The principal treat ment of patients with T1DM is initiation of insulin and diet 
control and careful monitoring of blood glucose levels. 
Long -acting insulin analogs have proven efficacy and offer good glucose control over 24 
hours for a single dose. Insulin glargine is a long- acting insulin analogue allowing once -daily 
administration to cover basal insulin requirements for over 24 hours. Mylan’s insulin glargine is a human insulin analogue of r -DNA origin produced in the host organism  Pichia 
pastoris . P pastoris  is a methylotr opic yeast that has been successfully used in the production 
of proteins.  
Extension Study Population:  Patients with an established diagnosis of T1DM per ADA 
2014 criteria  [4] who were randomized to the Lant us
® treatment arm of the MYL -GAI-3001 
study, and who have completed the 52- week treatment period on Lantus® will be eligible to 
be screened for  the MYL -1501D -3003 study . 
 Background and Rationale  
Mylan’s insulin glargine is being developed globally as a biosim ilar to Lantus. In the US , this 
development is currently  following the 505(b)(2) pathway , but will according to the US 
Food, Drug and Cosmetic (FD&C)  Act in the future follow the 351(k) pathway. Hence, 
criteria for both regulatory pathways will be pursued.1 
The aim of this extension study is to demonstrate that Mylan’s insulin glargine and Lantus® 
have equivalent  safety and efficacy in T1DM patients, when one treatment is substituted with 
the other. Under the 505(b)(2) pathway this is called “therapeutic equivalence” while under 
                                                 
1  By March 23, 2020 insulin glargine under section 505 of the FD& C Act shall be deemed to be licensed under section 351 
of the Public Health Service (PHS)  Act (see section 7002(e)(4) of the BPCI Act) (ref: FDA draft guidance: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM490264.pdf ) as a 
biosimilar  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 22 
 351(k) this is termed “interchangeability”. Following th e transition from 505(b)(2) to 351(k), 
the clinical equivalence data will be considered to support the interchangeabili ty of Mylan’s 
insulin glargine and Lantus.  Although FDA has not yet issued clear  guidelines on 
interchangeability, interactions  with the Agency indicate that in order to show 
interchangeability between the reference drug and the test drug , the primary end point should 
be assessed for equivalence between two treatment arms ; one exposed to continuous use of 
reference and one exposed to repeated switches, which is  defined as at least four (4)  periods 
of adequate durations  [three (3) switches or transitions] . Within  the 3 switches, the patients 
will be  switched from reference drug to test drug and back again. The Lantus® arm of MYL -
GAI-3001 will represent the first of the four periods.  
The extension study will be conducted open- label since the 2 formulations have different 
manufacturers and thus distinct packaging. To avoid bias in the evaluation of the critical 
endpoints, blinded analysis of immunogenicity and HbA1c data is planned.  
Patients who successfully complete d 52 weeks in MYL -GAI-3001 will be eligible  to 
participate in  the extension study. Patients exposed to different types of insulins may have 
different immune responses following exposure to trial drug. This confounding effect will be 
minimized  as only patients who have been on Lantus® (besides mealt ime insulin lispro ) for 
the last 52  weeks prior to the randomization will be included in the trial.  
Patients on Lantus® during MYL -GAI-3001 will be randomized to Mylan’s insulin glargine 
or Lantus® for 12 weeks; following which, those on Mylan’s insulin glargine will be 
switched to Lantus®, and those on Lantus® will continue on Lantus® for another 12 weeks. 
During the consecutive 12- week comparative treatment periods, diabetes treatment will be 
either maintained or further controlled (if needed) by titrating the dose of Lantus® or Mylan’s 
insulin glargine , if necessary.  After the 24 weeks of treatment, those patients who were 
randomized to Mylan’s insulin glargine and had a switch to Lantus® will und ergo an 
additional switch to Mylan’s insulin glargine for an additional 12 weeks to complete the third treatment period. Those patients who are on Lantus
® since the start of the study  and did not 
have any switch  will continue on Lantus® for another 12 weeks to complete the third 
treatment period.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 23 
 All patients will continue  on insulin lispro for the entire duration of the study. After 
completion of the 36 week treatment, patients will go back to the approved medications (as 
prescribed  earlier, prior to their participation in the MYL -GAI-3001 study ) on their own and 
will be followed up for safety for another 4 weeks (Mylan will not provide any medications 
during the safety follow -up period). The 36 to 40 week safety data will be captured . This 
4-week follow -up visit is to  confirm that patients are safe on the prescribed medications.  
Twelve week s exposure  is considered adequate to assess the efficacy with respect to HbA1c , 
as well as to compare the safety between the treatment  groups. If sw itching from Lantus® to 
Mylan’s insulin glargine or from Mylan’s insulin glargine to Lantus® have an impact on the 
efficacy or the safety , a discernible difference in efficacy  or safety parameters is expected  
versus the group of patients who are continuing  on Lantus® throughout.  
 Clinical data on Lantus®  
The only reference safety document for Mylan’s insulin glargine is the Investigator’s 
Brochure [ 6]. The only reference safety document for the comparator is the current United 
States P rescribing Information of Lantus® [7]. 
 
 STUDY OBJECTIVES AND ENDPOINTS  
 Objectives   
To compare the following variables when Mylan’s insulin glargine and Lantus® are 
interchanged:  
Primary objective  
• Demonstrate the equivalence of changes in HbA 1C between two treatment  
sequence groups  
Secondary objective  
• Change in basal insulin dose per unit body weight (U/Kg /day)  
• Immunogenicity: incidence and change from baseline in the relative levels of 
ADA, incidence and change from baseline in the relative levels of anti -HCP 
antibodies.  
• Rate of hypoglycemic events per 30 days; and occurrence of hypoglycemia  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 24 
 • Occurrence of local reactions, systemic reactions and other adverse events  
• Change in fasting plasma glucose  
• Change in 8 -point SMBG profile  
• Device- related safety assessments  
 STUDY DESIGN 
A schematic representation of the extension study is given in Figure  1. This multi- center, 
open- label, randomized clinical extension study in patients with T1DM will assess 
interchangeability of Mylan’s insulin glargine and Lantus® with respect to the safety  and 
efficacy.  
Patients with an established diagnosis of T1DM per ADA 2014 criteria who were 
randomized to the Lant us® treatment arm of the MYL -GAI-3001 study, and who have 
completed the 52- week treatment period on Lantus® will be eligible to be screened for the 
MYL -1501D -3003 extension study. All patients will continue on insulin lispro for the entire 
duration of the study.  
There will be 2 treatment arms ( with 3 sequences) in the extension study.  
• Patients randomized to Lantus® during MYL -GAI-3001 study  will be randomized to 
either Lantus® or Mylan’s insulin glargine for 12 weeks .  
• After this first 12 weeks of treatment, tho se on Mylan’s insulin glargine will be 
switched to Lantus® while those on Lantus® will be continued on Lantus® for another 
12 weeks to complete the second treatment period.  
• After  the 24 weeks of treatment, those p atients which  were initially randomized to 
Mylan’s insulin glargine  and had a switch to Lantus® will have an additional switch  to 
Mylan’s insulin glargine for additional 12 weeks  to complete the third treatment 
period. Those on Lantus® since the start of the study , who did not ha ve any switch  
will continue on Lantus® for another 12 weeks to complete the third treatment period. 
After 36 weeks of treatment, patients will go back to the approved medications (as prescribed  
earlier ) and followed up for safety for another 4 weeks. The 36 to 40 week safety  data will be 
captured /documented (Mylan will not provide any medications during the safety follow -up 
period) . 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 25 
 During the 36- week treatment period, the titration  (if needed) of both Mylan’s insulin 
glargine and Lantus® should be kept to a minimum  and the recommended titration algorithm 
should be followed, unless there are safety concerns.  
The week 52 visit for the MYL -GAI-3001 study will  also serve as the week 0 visit for the 
extension study.  
 Study Duration  
The maximum possible duration of patient participation in the extension study is 
approximately 40 weeks, which includes:  
• Treatment period 1: 12 weeks of r andomized comparative treatment  (Week 0 to 
Week 12) .  
• Treatment period 2: 12 weeks of randomized comparative treatment  (Week 12  
to Week 24) .  
• Treatment period 3 : 12 weeks of randomized comparative treatment  (Week 24  
to Week 36 ).  
• Follow -up period: 4 weeks  of follow -up visit (Week 36 to Week 40)  
Number of Patients :  
From  approximately  70 selected sites, approximately 69 patients will be included in each 
arm, with a target of approximately 138 randomized patients in both arms together.  
 Allocation to Treatment  
Patients on Lantus® will be randomized 1:1 to receive either Mylan’s insulin gla rgine 
or Lantus® using an IVRS/IWRS. Change of dosing from morning to bedtime or vice versa 
will not be permitted.  
If a patient discontinues, the patient will not be allowed to re -enter the extension study.  
 Patient  Numbering  
The center numbers will remain  the same as those assigned  by the sponsor/designee in 
MYL -GAI-3001. New u nique randomization numbers will be assigned by the IVRS/IWRS 
system to the patients enrolled into the MYL -1501D -3003 extension study.   
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 26 
 
 Blinding  
This is an open- label study. To minimize bias, treatment assignments will not be revealed to 
the central laboratory for the safety (immunogenicity) and efficacy (HbA1c) analyses. A 
document  listing the  trial team members who are blinded and unbl inded will be maintained . 
  Breaking the Bli nd  
The Investigator and the patients will not be blinded to treatment assignments .   
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 27 
                                                                                                                    
 
                                                                                                                              
                                                                                                                                                       
 
 
Figure 1 : Study Flowchart  
 
Randomization (1:1)  
Mylan's Insulin Glargine 
plus insulin l ispro  
(12 weeks)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Mylan's Insulin Glargine 
plus insulin l ispro   
(12 weeks)  
 
 
Lantus®  
plus insulin l ispro   
(12 weeks)  
Lantus®  
plus insulin l ispro   
(12 weeks)  
Lantus®  
plus insulin l ispro   
(12 weeks)  
 
   
Lantus
®  
plus insulin l ispro   
(12 weeks)  
 
End of Trial Visit  
(36 weeks)  
Follow -up Visit  
(40 weeks)  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 28 
 
 PATIENT  SELECTION  
 Inclusion Criteria  
Patients must meet all of the following inclusion criteria to be eligible for enrollment into the 
extension study:  
1. Patients who have completed the 52- week treatment period  (irrespective of their age at 
the completion of MYL -GAI-3001)  of MYL -GAI-3001 and were assigned to Lantus® in 
that study .   
2. Patients or their legal representatives  must give written and signed informed consent 
before starting any protocol -specific procedures.  
3. The patient is able and willing to comply with the requirements of the extension study 
protocol including the 8- point SMBG, completion of patient diary records  as instructed  
and following a recommended diet and exercise plan for the entire duration of the 
extension study.  
4. Female patients complying with the following:  
• Female patients of childbearing  potential must be using oral contraception or two 
other acceptable methods of contraception, (e.g., intra -uterine device plus condom, 
spermicidal gel plus condom, diaphragm plus condom, etc.)  from the time of 
randomization throughout the entire study . 
• Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception. 
• Postmenopausal females must have had no menstrual bleeding for at least 1 year prior to inclusion in MYL -1501D -3003 study .  
• Female patients who report surgical sterilization must have had the procedure at least 
6 months prior to inclusion to MYL -1501D -3003 study.  
• All female patients of childbearing potential, must have negative pregnancy test 
results at baseline (week 0) and at each clinic visit as per the SCHEDULE OF 
ACTIVITIES . 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 29 
 • If female patients have male partners who have undergone vasectomy, the vasectomy 
must have occurred more than 6 months prior to inclusion in MYL -1501D -3003 
study.  
 Exclusion Criteria  
Patients meeting any of the following criteria will not be included in the extension study:  
1. History or presence of a medical condition or disease that in the Investigator’s 
opinion would place the patient at an unacceptable risk from trial participation. 
2. History of clinically significant (i.e., significant enough to alter the insulin dose require ment, as per the Investigator) acute bacterial, viral or fungal systemic 
infections in the 4 weeks prior to inclusion / randomization (recorded while collecting patient history)  into MYL -1501D -3003.  
3. Patients scheduled to receive another investigational dru g during the extension study 
period. 
4. Any major elective surgery requiring hospitalization planned during the extension study period.  
5. Moderate insulin resistance, defined as requiring ins ulin ( basal + prandial ) of 
≥1.5 U/kg/day (Lantus
® in U/kg/day or Mylan’s insulin glargine in IU/kg/day).  
 STUDY TREATMENTS AND CONCOMITANT MEDICATI ON 
The investigational products used in this trial are Mylan’s insulin glargine and Lantus® (from 
Sanofi -Aventis). All patients will receive insulin lispro as mealtime medication.  
 Study Medication  
• Mylan’s insulin glargine (test product) 100 IU/mL  
• Lantus® 100 U/mL  (Sanofi -Aventis), sourced from the US (USLD , reference product)  
Both investigational products will be provided by the sponsor in pre -filled disposable pens 
with a 3  mL ca rtridge. Mylan’s insulin glargine formulation for injection is a sterile, clear 
solution with a pH of 4. Each mL contains 100 units of insulin glargine (equivalent to 3.64 mg). The excipients of the formulation are identical to those of Lantus
® [6]. Please refer to 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 30 
 the Investigator’s Brochure [ 6] for more details on Mylan’s insulin glargine, and the United 
States prescribing information [ 7] for more details on Lantus®.  
At the end of MYL -GAI-3001, an equivalent dose  (dose of Lantus® at the end of MYL -GAI-
3001)  of Mylan’s insulin glargine  or Lantus® (based on the assigned treatment) will be 
provided for 12 weeks. For the following 12 weeks, patients on Mylan’s insulin glargine will 
receive the same dose of Lantus®; while patients on Lantus® will continu e on the same dose 
of Lantus®. After 24 weeks of treatment, those patients who were randomized to Mylan’s 
insulin glargine and had a switch to Lantus® will undergo an additional switch to Mylan’s 
insulin glargine for an additional 12 weeks to complete the third treatment period. For those 
patients who are on Lantus® since the start of the study  and did not ha ve any switch will 
continue on Lantus® for another 12 weeks to complete the third treatment period. 
Change in dose should be made only if there is safe ty concerns  as per the Investigator ’s 
judgement .  
 Mealtime insulin  
• Humalog® (insulin lispro injection, 100 U/mL), manufactured by Eli Lilly 
(administered in Humalog Kwikpen® - disposable pens).  
The mealtime insulin will be provided by the sponsor.  
HUMALOG 100 units per mL (U -100) is available as 3 mL Humalog KwikPen (prefilled) .  
Complete information on Humalog® and the Humalog Kwikpen® - disposable pen is 
available in the Humalog® SmPC and US prescribing information [ 10,11].  
All patients will continue on insulin lispro for the entire d uration of the study. The  
Investigator will inform the patients of the doses to be used and the titration scheme to be 
followed (if needed during the study) . During the trial period dose titration  (if needed)  will be 
kept to a minimum.  
 Ancillary  Supplies  
The following ancillary supplies will be provided by the sponsor: glucose monitor, control 
solution for calibration of the glucometer, glucose monitor strips, alcohol swabs, lancet 
device, disposable lancets, sharps container, insulated bag to transport insulin, needles, and 
patient diary.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 31 
 
 Drug Storage  
The Investigator must ensure the availability of proper storage conditions and temperature 
monitoring equipment at the site. A temperature log for trial products stored at the site must 
be maintained . The Investigator or Investigator’s authorized staff will check the storage 
temperature daily on working days and record the results in the temperature log. If storage conditions deviate from the described storage conditions or the medication is damaged in any 
way, the monitor must be contacted without delay. The monitor must notify the sponsor of 
any temperature deviations or damaged products. The sponsor or designee will assess the extent of the temperature deviation or damage and will inform the monitor in wri ting whether 
the product may be used or not. 
Mylan’s insulin glargine 100 IU/mL  
Unopened Mylan’s insulin glargine disposable pen injector:  Mylan’s insulin glargine 
should be stored in a refrigerator (2°C to 8°C). It cannot be used if it has been frozen.  
Open (In- Use) Mylan’s insulin glargine disposable pen injector:  Mylan’s insulin glargine 
can be kept at room temperature (below 25ºC) for up to 28 days once the disposable pen has been put to use. It should not be exposed to heat or direct sunlight. It sho uld never be used 
after the expiry date printed on the pack.  
Lantus
® 100 U/mL  
Unopened Lantus® disposable insulin pen injector:  Lantus® should not be stored in the 
freezer and should not be allowed to freeze. Lantus® if it has been frozen  should not be use d. 
Unopened Lantus® pen injectors should be stored in a refrigerator at 2°C –8°C, and discarded  
in case expired at the end of the study based on the Sponsor instructions . Unopened Lantus® 
pen injectors kept at room temperature should be discarded at the end  of the study based on 
the Sponsor instructions .  
Open (In- Use) Lantus® disposable insulin device:  The opened (in -use) Lantus® pen 
injector should not be refrigerated but should be kept at room temperature (below 86°F /30°C ) 
away from direct heat and light.  The opened (in -use) Lantus® pen injector must be discarded   
at the end of the study based on the Sponsor instructions  . 
Please refer to the United States prescribing information for storage conditions for Lantus® 
[7]. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 32 
 Humalog® 
Please refer to the Summary of Product Characteristics  [10] (if Europe sourced) or US 
prescribing information [ 11] (if US sourced) for Humalog® storage instructions.  
Humalog® should not be used after the expiration date. Unopened HUMALOG should be 
stored in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use 
HUMALOG if it has been frozen. In- use HUMALOG KwikPen should be stored at room 
temperature, bel ow 86°F (30°C) and must be used within 28 days or be discarded at the end 
of the study based on the Sponsor instructions , even if they still contain HUMALOG. It 
should be protected from direct heat and light  (Table 1) .  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 33 
 Table 1: Humalog Kwikpen Usage Instructions  
 Not In -Use (Unopened) 
Room Temperature 
(Below 86°F [30°C])  Not In -Use (Unopened) 
Refrigerated  In-Use (Opened) Room 
Temperature, (Below 
86°F [30°C])  
3 mL Humalog KwikPen 
(prefilled)  28 days  Until expiration date  
 28 days, do not 
refrigerate.  
 
 
 Drug Accountability  
The sponsor will supply sufficient quantities of the investigational product to allow 
completion of this extension trial. Upon receipt of the investigational product supplies at the 
site, the designated trial staff member should count and verify that the s hipment contains all 
the items noted in the shipment inventory.  
The Investigator or designated staff must notify the monitor if there was a temperature 
deviation during shipment to the site (if information is available) or if the products are in any 
way d amaged  (Temp Tale® information should ensure accurate temperature monitoring ). The 
Investigator or designee should temporarily quarantine compromised drug until notified by 
the monitor of actions to be taken (release for use or permanent quarantine for ret urn and 
destruction). The monitor must notify the sponsor of any temperature deviations or damaged 
products. The sponsor or designee will assess the extent of the temperature deviation or 
damage and will inform the monitor in writing whether the product ma y be used or not.  
The Investigator must keep complete and accurate records for the receipt, storage, 
dispensing, and return or destruction of investigational products and mealtime insulin.  
 Dispensing  
It is the responsibility of the Investigator to ensure that investigational products and mealtime 
insulin are dispensed only to trial patients. The Investigator or designee will dispense the 
required number of investigational product doses to ensure that the trial patient has sufficient supplies until the next dispensing visit.  
Patients will be requested to return all used and unused medications to the site at each visit. The usability of the returned medications will be assessed. Returned medications may be 
again dispensed to the same pa tient, provided it was stored as per specification and will not 
cross the expiry date before the next visit.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 34 
 The site will store the returned medication until the monitor has performed accountability 
and informs the site of the processes for destruction or return of the medication.  
 Administration  
Insulin glargine should be administered as a subcutaneous injection. It should be taken at approximately the same time every day. The preferred site is in the abdomen. The other 
possible sites of administration a re the upper arm and thigh (upper leg). The injection sites 
should be rotated to reduce risk of lipodystrophy. Refer to the Investigator’s Brochure [ 6] 
and US prescribing information [ 7]. Insulin lispro will be administered as per the 
Investigator’s advice and as per the prescribing information [ 10,11].  
The dosage of insulin will be  adjusted based on SMBG profile , performed by the  patients at 
home , so that patients attain the following glycemic targets (ADA 2014 criteria)  [4]: 
• Fasting pre -prandial SMBG between 70 to 130 mg/dL (3.9 -7.2 mmol/L)  
If the measured SMBG is <70  mg/dL (3.9 mmol/L) or if the patient has symptoms suggestive 
of hypoglycemia, he/she can call  the Investigator or designee , if required . The insulin dose 
will be altered by the Investigator or designee, if required, based on the values. Any increase 
in total insulin do se per day of >6 units during any titration step should be performed with 
caution.  
 Return of S tudy D rug 
After the completion of the extension study, the monitor will perform the final drug 
accountability check and inform the site of the return/destruction procedures for the unused 
and partly used medication.  
 Treatment Compliance  
All reasonable and appropria te methods will be used to ensure compliance to the protocol for 
administration of trial medication.  
 Concomitant Medication  
Other than study drugs, insulin, insulin analogs and other anti -diabetes medications as well as 
glucocorticoid therapy (oral, intra venous, inhaled or other routes that produce systemic 
effects) should not be taken during the study (prohibited medications). A list of restricted 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 35 
 medications that may interfere with insulin is given in  Table 2. No drugs listed in this table 
should be started during the treatment period.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 36 
 Table 2: Medications That Are Likely to Interfere w ith Diabetes Control  
Drug classes that are known to augment the 
blood glucose lowering effect of insulin such as:  Drugs and drug classes that are known to decrease 
the blood glucose lowering effect of insulin such as:  
1. salicylates at doses more than >2 g/day 
2. sulfa antibiotics  
3. angiotensin converting enzyme inhibitors  
4. disopyramide  
5. fibrates  
6. fluoxetine  
7. monoamine oxidase inhibitors  
8. propoxyphene  
9. pentoxifylline  
10. somatostatin analogs  
11. bromergocryptine ( bromocryptine)  
12. anabolic steroids . 
 1. danazol  
2. niacin  
3. diuretics  
4. sympathomimetic agents  
5. glucagon  
6. isoniazid  
7. somatropin  
8. thyroid hormones  
9. oral contraceptives  
10. estrogens  
11. progestogens  
12. protease inhibitors  
13. phenothiazine derivatives  
14. atypical antipsychotic medications (e.g. 
olanzapine and clozapine).  
 
All treatments being taken by the patients following signing the ICF in addition to the trial 
treatment (investigational products and mealtime insulin) during the trial are regarded as 
concomitant medications and must be documented in the CRF. Mylan’s insulin glargine,  
Lantus® and insulin lispro  will not be considered as concomitant medications. 
 STUDY PROCEDURES  
This trial includes randomized comparative treatment period -1, randomiz ed comparative 
treatment period -2, randomized comparative treatment period -3 and a follow -up period. 
Specific activi ties involved in each period are described in the SCHEDULE OF 
ACTIVITIES . 
Throughout the trial , every reasonable effort should be made to follow the t iming of 
assessments and procedures for each patient. Deviations from the schedule should be avoided. The allowed time window for each visit is shown in the SCHEDULE OF 
ACTIVITIES . 
 Visit Schedules and SMBG Profiles  
Table 3 shows the SMBG profiling requirements at each visit.  
 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 37 
 Table 3:  SMBG Profile Requirements by Visit  
 Weeks 0 to 36  Week 40 (FU)  
Mandatory clinic visit with 3 day 8-point SMBG in the week 
preceding the visit  Week 0 to week 
36 visits  - 
Telephone visit  As advised by the 
Investigator  SMBG will be 
performed  for FU visit,  
as suggested  by the 
Investigator at Week 
36 visit (EOT)*  
*Additional visits or profiles to be performed as advised by the Investigator  
EOT: end of treatment; FU: follow -up visit: SMBG: self -monitored blood glucose.  
 Patient  Withdrawal  
If, for any reason, a patient discontinues the trial prematurely, the patient may be followed up 
upon consent and as described in the following withdrawal criteria : 
Following are the  withdrawal criteria:  
1. Withdrawal of consent.  
2. For female patients, diagnosis of pregnancy or  stated intention to become pregnant. 
Effort should be made so that the pregnant women still report to the site and are 
followed until delivery or termination.   
3. Repeated protocol non- compliance.  
4. At the investigator’s discretion  (following discussion with t he sponsor medical 
monitor), for safety issues such as severe hypoglycemia or hypoglycemic unawareness. The site should follow -up these patients as  per the SCHEDULE OF ACTIVITIES  until 
the 40 week follow -up call. 
5. At the investigator’s discretion , (following discussion with the sponsor medical 
monitor), in certain situations such as significant intercurrent illness, hospitalization for surgery, or an SAE . The site should follow -up these patients as per the SCHEDULE OF 
ACTIVITIES  until the 40 week follow -up call.  
Invest igators  must attempt to contact  patients who fail to attend scheduled visits  (by 
telephone or other means) , to exclude the possibility of an AE being the cause of withdrawal. 
Should an AE be the cause for withdrawal , the AE must be documented, reported, a nd 
followed- up as described in S ection 8. If withdrawal was not due to an AE the 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 38 
 Investigator  should inquire about the reason for withdrawal . If applicable, request all 
withdrawn patients to bring back all unused investigational product(s) and return them at  the 
final visit. The attempts  to contact patients who fail to attend scheduled visits should be 
documented in the patient files as should the reasons for withdrawal.  
No further evaluations should be performed, and no additional data should be collected if the 
patient withdraws from t he trial  and also withdraws consent for disclosure of future 
information. Data collected before patient  withdrawal of consent  will be retained and 
continue to be used, or destroyed if required per local regulation and rules . 
 STUDY ASSESSMENTS AND METHODS  
 Handling of Blood Samples  
Laboratory analysis will be conducted at central laboratories identified by the sponsor. The 
laboratory will provide specific sample kits to the Investigator site prior to the visit of 
patients. Instructions for collecting, handli ng, storing and shipping samples will be provided 
in the laboratory manuals.  
 Efficacy Assessments  
7.2.1.  HbA1c  
HbA1c assessments will be performed as shown in the SCHEDULE OF ACTIVITIES . The 
measurement will be performed by the central laboratory for safety and efficacy samples.  
7.2.2.  Fasting Plasma Glucose (FPG)  
FPG assessments will be performed as shown in the SCHEDULE OF AC TIVITIES . The 
measurement will be performed by the central laboratory for safety and efficacy samples.  
7.2.3.  Body Weight and BMI  
Weight will be recorded by the site as specified in the SCHEDULE OF ACTIVITIES . The 
Investigator will calculate the BMI  (using the formula BMI=weight in kg/ height in m2; for 
BMI calculation, the previous r ecorded weight will be used until new weight recording).  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 39 
 7.2.4.  8-point  SMBG profiles  
8-point  SMBG profile measurements will be performed by the patient at home and recorded 
in the patient diary, as specified in the SCHEDULE  OF ACTIVITIES . One 8-point  SMBG 
profile set includes measurements of SMBG values on 3 day s, performed in the week 
preceding the next visit  (of the three days , 2 should be consecutive) . The tim e points  for the  
8-point SMBG are provided in Appendix III . The patient should document the 3 pre -visit 
measurements in the diary , and will be advised to similarly document any a dditional 
estimations.   
On days in which SMBG is not mandated by protocol, patients will be advised to 
self-monitor their blood glucose 4 times a day.  
7.2.5.  Daily Insulin Doses  
Patients will be asked to document the dose of Mylan’s insulin glargine/Lantus® and insulin 
lispro  taken on the days when they perform 8- point SMBG  profi les (from week 0 to week 
24). Doses must be recorded  in the patient diary . This data will be transcribed to the eCRF 
after the patient diary is collected , by the Investigator or designee.  The patient should 
document the 3 pre -visit doses in the diary; and will be advised to document any additional 
doses . 
 Immunogenicity Assessments  
Blood samples for the assessment of immunogenicity  will be collected as specified in the 
SCHEDULE OF  ACTIVITIES  and in the table below  (Table 4) .  
Table 4: Blood V olume N eeded for I mmunogenicity A nalysi s 
Assessme
nts Randomiza
tion3  2 
wee
ks 4 
wee
ks 8 
wee
ks 12 
wee
ks 14 
wee
ks 16 
wee
ks 20  
wee
ks 24 
wee
ks 26 
wee
ks 28 
wee
ks 32 
wee
ks 36 
wee
ks 
 Volume Collected (mL)      
Anti-drug 
antibody 
(ADA)1 15  10 10 10 10 10 10 10 10 10 10 10 10 
Neutralizi
ng 
Antibody 
(NAb)1 5 5 5 5 5 5 5 5 5 5 5 5 5 
Anti-HCP 
Antibody1 5 5 5 5 5 5 5 5 5 5 5 5 5 
Drug 6 6 6 6 6 6 6 6 6 6 6 6 6 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 40 
 Assessme
nts Randomiza
tion3  2 
wee
ks 4 
wee
ks 8 
wee
ks 12 
wee
ks 14 
wee
ks 16 
wee
ks 20  
wee
ks 24 
wee
ks 26 
wee
ks 28 
wee
ks 32 
wee
ks 36 
wee
ks 
 Volume Collected (mL)      
concentra
tion2  
1Blood samples will be drawn into serum separator tubes (SST).  
2Blood samples will be drawn into K 2EDTA plasma tubes.  
3Results of the s amples collected as part of MYL -GAI-3001 trial will be used.  
The clinical laboratory will provide specific sample kits to the Investigator site prior to the 
visit of patients. Instructions for collecting, handling, storing and shipping of clinical samples 
will be provided in the laboratory manuals. Samples  and lab r esults  collected at 
randomization will be considered as baseline.  
The central laboratories are:  
Samples from Europe will be sent to  
 Q2 (Squared) Solutions  
The Alba Campus , Rosebank 
 Livingston , EH54 7EG  
UK 
Samples from US will be sent to  
 Q2 (Squared) Solutions27027 Tourney Road, 
Suite 2E  
Valencia, CA  91355  
USA  
 
The site must store the immunogenicity and drug concentration samples at - 20°C ± 5°C or 
lower and ship the samples in batches on a monthly basis to the central laboratory where they will be stored at - 80 ± 5°C or below. Primary and backup samples should not be sent in the 
same shipment.  Both  immunogenicity and drug concentration samples must be shipped 
frozen on dry ice. Temperature monitoring devices (e.g. Temp Tale
®) must be include d in all 
sample shipments.  
7.3.1.  Anti- Drug Antibody  
Two conventional radioimmunoprecipitation assays (RIPA) were employed for the 
assessment of anti -drug antibodies ( ADA) .  A two assay approach , applied in a blinded 
fashion, was utilized due to the potential structural differences between drug products arising 
from the different host cells used in production.  The two assays were identical except for the 
use of  a unique  tracer: 125I-Lantus , designated for the ‘LAN assay’, and 125I-MYL IG , 
designated as the ‘MIG assay’.  In both assays s ample s underwent a pre -treatment step that 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 41 
 included acid dissociation to release any anti -insulin antibodies complexed with free drug, 
followed by charcoal adsorption of the free insulin analog.  The treated samples were then 
incubated with a fixed amount of each tracer under the following conditions:  
• Assay buffer only  (no inhibitor)  
• Assay buffer containing excess unlabeled MYL IG  
• Assay buffer containing excess unlabeled Lantus  
• Assay buffer conta ining excess unlabeled Human Insulin  
ADA c omplex formation  with the tracers is measured via gamma counting and expressed as 
a percentage of bound to total radioactivity (%B/T). 
 
In keeping with t he multi- tiered sample analysis recommendations for immunogenicity 
testing from published white papers ( 12, 13) , and current  regulatory guidance ( 14), the assay 
design employed a screening tier (no inhibition), confirmatory tier (competitive inhibition with excess drug), and characterization tier (competiti ve inhibition with excess human 
insulin) that were assessed simultaneously.  Since i nhibition with excess drug  and human 
insulin were  included within the  assessment of each sample, the total anti- drug antibody and 
insulin cross reactivity results were repo rted in terms of percent specific binding (%SB), 
which is the difference between the %B/T for the uninhibi ted and the inhibited samples for 
each assay.   Analogous to t iter values, the %SB is the relative amount of antibody present in 
the samples.   Cut-points for these assessments were determined based on %SB during assay 
validation and applied during sample analysis for scoring total a nd cross reactive ADA 
positive samples : 
 
 
 
 
 
 
In addition, drug- specific ADA was assessed by determining the %B/T difference between 
samples inhibited with excess Lantus and MYL IG in each assay:  
 Assay  Assessment  Assessment Definition  
MIG  Total ADA  %B/T (no inhibitor) - %B/T ( excess MYL IG ) 
Cross -reactive ADA  %B/T (no inhibitor) - %B/T (excess human insulin)  
LAN  Total ADA  %B/T (no inhibitor) - %B/T (excess LAN)  
Cross -reactive ADA  %B/T (no inhibitor) - %B/T (excess human insulin)  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 42 
 Assay  Assessment  Assessment Definition  
MIG  Drug specific ADA  %B/T (excess LAN ) - %B/T ( excess MYL IG ) 
LAN  Drug specific ADA  %B/T (excess MYL IG ) - %B/T (excess LAN ) 
 
For this assessment no cut -point was determined or applied, and the results are reported as 
%B/T.  
 
Drug concentration samples were obtained to support an alternative format for 
immunogenicity testing (bridging ELISA).  With the use of a RIPA format, drug 
concentration testing is not required.  
 Assessment of total antibody positive samples for the presence of neutralizing antibodies will 
be conducted at the discretion of the clinical team.  
7.3.2.  Antibodies against Host Cell Protein Antibodies (anti -HCP)   
The multi- tiered sample analysis approach for immunogenicity testing will also be employed 
for the detection of antibodies directed against host cell protein s present in the drug product. 
In keeping with the multi -tiered sample anal ysis recommendations for immunogenicity 
testing, the assay design employed screening (no inhibition), confirmatory (competitive 
inhibi tion with excess HCP ), and titer tiers.   However, since a high positive rate of pre -
existing antibodies i s anticipated due to ubiquitous exposure of the general population to 
yeast proteins, sample analysis i s limited to the screening and confirmatory tiers. Relative 
anti-HCP antibody levels over time will be estimated using sample ECL response in the 
screening  assay.  
The assay employed for anti -HCP antibody evaluation will be fully validated using a 
surrogate positive control antibody, developed from host cell protein antigens (Pichia  
pastoris). Host antigens for the reference product (from the host Escherichia  coli K12) are not 
available to develop a parallel assay for Lantus anti –HCP antibodies. In order to maintain 
blinded analysis, both treatment arms will be evaluated with the ass ay. Any change in the 
sample analysis method will be mentioned in the sample analysis plan.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 43 
 
 Safety Assessments 
7.4.1.  Medical History  
Medical history will be recorded at randomization and must include any  clinically relevant  
prior diagnosis, concomitant diseases and abnormalities, documentation of drug allergies, 
prior systemic and local allergic reactions to insulin. The medical history should be checked 
against the inclusion and exclusion criteria.  
7.4.2.  Prior and Concomitant Medication  
All treatments being taken by the patients at the time of randomization and all treatments given in addition to the trial treatment (investigational products), are regarded as concomitant 
treatments and must be documented in the eCRF.  
During the extension study the Investigator should ensure  that no medications listed in  
Table 2  are initiated.   
7.4.3.  Vital Signs  
Vital signs are body temperature, respiratory rate, sitting pulse, and blood pressure  (both 
systolic and diastolic) . The patient should be resting in sitting posi tion for at least 5 minutes 
before the measurements are performed. The vital signs will be recorded  as specified in the 
SCHEDULE  OF ACTIVITIES . 
7.4.4.  Physical Examination  
Complete physical examination data will be record ed as specified in the SCHEDULE OF 
ACTIVITIES  and will include the following assessments: general appearance, head, ears, 
eyes, nose and throat  (including thyroid) , skin, respiratory system, cardiovascular system, 
abdomen, lymph nodes, musculoskeletal system , gastrointestinal system (including mouth) 
and neurological system ; and  a diabetic foot examination .  
7.4.5.  Electrocardiogram  
A 12 -lead ECG will be done as specified in the SCHEDULE OF ACTIVITIES . The ECG 
will be performed in supine position after at least 5 minutes resting in the supine position. 
The results will be assessed qualitatively as normal or as abnormal with the abnormalities  
specified .  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 44 
 7.4.6.  Local and Systemic Allergic Reactions  
Local and systemic allergic reactions will be recorded as specified in the SCHEDULE OF  
ACTIVITIES . The Investigat or should ask the patient at each trial visit about allergic 
reactions and check the injection site(s) for possible local allergic reactions.  
If a patient develops any type of allergic reaction, routine evaluations for identifying the 
cause and type of all ergic reaction need to be done. These may include skin biopsy, blood 
sample collection for further testing, skin tests for detecting allergens or other standard methods considered essential by the Investigator.  
7.4.7.  Adverse Events and Serious Adverse Events  
Adverse events and SAEs will be recorded as specified in the SCHEDULE  OF ACTIVITIES  
from  the time of sign ing the informed consent form until the end of the follow -up visit . After 
the follow -up visit, any SAEs reported by the patients will be recorded if th ey are deemed 
related to trial drugs by the Investigator.  
7.4.8.  Hypoglycemic Events   
Patients will be instructed to record all hypoglycemic events in the patient diary from week  0 
through the EOT visit. The hypoglycemic events will be reviewed by the Investigator and 
transcribed into the eCRF by the Investigator or designee after the diary has been collected.  
Details of the different types of hypoglycemic events are provided in section 7.5.6.1. Severe 
and serious hypoglycemic episodes will be reported to the sponsor immediately , according to 
section 8.3.2.8. 
7.4.9.  Safety Related to Device Use  
Adverse events could potentially result from device failure or user error. These safety issues 
will be identified, documented, investigated and if appropriate, reported. Any SAE associated 
with a device issue will be reported to the sponsor immediately acc ording to section 8.3.2.8.  
7.4.9.1. Adverse Events Associated with Device and Device Complaints  
All AEs associated with the device will be captured according to section 8.3, including an 
assessment of causality by the Investigator. Any device- related complaints will be 
investigated at the discretion of the sponsor. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 45 
 7.4.9.2. Investigator’s Responsibility  
• During enrollment, patients will be instructed to document in their diary and inform 
the Investigator (during the next scheduled visit) about any difficulties encountered 
during the administration of the drug.  
• Patients will be instructed to immediately report to the Investigator any suspected 
failure of the device to deliver the intended dose,  or an SAE associated with the 
device.  
• For AEs associated with use of the device, the Investigator will record the AE term in 
the eCRF to capture both the adverse consequence as well as the association with the device (e.g. injection site pain from acciden tal needle stick).  
• The Investigator will record in the eCRF whether or not the device issue resulted in 
an AE; an assessment of whether the AE was related to the drug, the device, or both; 
and any other relevant information about the patient’s condition. 
• Any device -related complaint resulting in an SAE will be reported to Mylan within 
24 hours  (per section 8.3.2.8).  
• Even in the absence of a report by the patient of device failure or a device related AE, if the Investigator sees that the pen is broken/damaged or disassembled, the 
Investigator will replace the device and send the damaged device to the CRO/Mylan.  
7.4.9.3. Sponsor ’s Responsibility  
• For SAEs, Mylan will independently evaluate whether the SAE was drug -related or 
related to an adverse device effect.  
• In the event that the information available in the eCRF is inadequate for root cause 
analysis, Mylan will send a questionnaire to the Investigator, asking for more details.  
• All SAEs related to the use of the needle, which is a legally marketed device, will be recorded and reported to Mylan for investigation and reporting to the needle 
manufacturer, if deemed necessary, based  on the outcome of the investigation.  
• Information regarding the circumstances, evaluation, investigation and analysis of all 
device deficiencies will be included in the clinical study report (CSR).  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 46 
 7.4.10.  Safety Laboratory Assessments  
Safety and efficacy laboratory assessments will be performed by the following central 
laboratory:  
Table 5: Central Laboratory Details for Safety Sample Shipmen t 
Samples from Europe will be sent to  
 Q2 (Squared) Solutions  
The Alba Campus , Rosebank 
 Livingston , EH54 7EG  
UK 
Samples from US will be sent to  
 Q2 (Squared) Solutions27027 Tourney  Road , 
Suite 2E  
Valencia, CA  91355  
USA  
 
7.4.10.1. Hematology, Blood Chemistry, and Urine Analysis  
Blood samples for hematology, blood chemistry, and urine samples for urine analysis will be 
collected and analyzed as specified in the SCHEDULE OF ACTIVITIES . 
Hematology panel includes hemoglobin, hematocrit, white blood cell count with 
differentials, red blood cell count with indices (mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration) and platelet count.  
Blood chemistry panel includes blood urea / BUN, serum creatinine, creatinine kinase, uric 
acid, serum bilirubin (total and direct), total protein, serum albumin, ALT, AST, alkaline 
phosphatase, LDH, lipase, sodium, potassium, calcium, magnesium, chloride, and 
bicarbonate.  
For the urinalysis a routine urine dip will be performed by the site using supplies provided by 
the central laboratory. This will include assessment of specific gravity, pH , and semi -
quantitative "dipstick" evaluation of glucose, protein, bilirubin, ketones, leukocytes and blood. If the Investigators want to do detailed urine testing , the site will send a urine sample 
to the central laboratory for microscopic evaluation. Microscopic examination will include WBC, RBC, casts, cast type, cry stals, epithelial cells, renal cells, mucus threads, bacteria, 
yeast, and Trichomonas . 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 47 
 7.4.10.2. Fasting Lipid Profile  
Blood samples for fasting lipid profiles will be collected and analyzed as specified in 
the SCHEDULE OF ACTIVITIES . The lipid profile includes total cholesterol, high density 
lipoprotein (HDL), LDL and triglycerides . For this protocol ‘fasting’ will be defined as no 
intake of food or drink ( except water) for at least 10 hours.  
 Other Assessments  
7.5.1.  Demographic V ariables  
Demographic variables will be documented at visit 1  and include date of birth (in Germany , 
only age OR year of birth ), gender  and race (Asian, American Indian, Alaska Native, Bla ck, 
Caucasian, Hispanic, Native Hawaiian, Hispanic, other s).  
7.5.2.  Pregnancy Test  
Pregnancy tests will be perform ed as specified in the SCHEDULE OF ACTIVITIES . Sites 
will receive test strips for the urine pregnancy tests from the central laboratory. The result of 
the urine pregnancy tes t must be available before trial  medication is dispensed. Durin g the 
week 0 , visit 1, the medication will be dispensed after confirming the urine pregnancy test  
performed during EOT visit of MYL -GAI-3001 study  is negative. 
7.5.3.  Study Treatment Non -Compliance  
Patient s will be identified a s study treatment non -compliant  if they meet any of the following 
criteria:  
• Missing either total meal time insulin or basal insulin doses for 5 consecutive 
days.  
• Missing either total meal time insulin or basal insulin doses for more than 30 accumulative days for completer or more than 20% treatment days for drop- out  
• Taking more than one administration of basal insulin (If multiple injections are 
required to delive r the required quantity of drug due to logistic reasons , then it is 
considered as one administration)  for 10 days cumulative  
• Taking more than the prescribed basal insulin dose for more than 30 days 
cumulative.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 48 
 7.5.4.  Dilated Ophthalmoscopy  / retinal photography  
Dilated Ophthalmoscopy / Retinal photography testing should be performed once within one 
of the visits during the 28 days of enrolment .  
7.5.5.  Patient Diary  
Patients will receive patient diaries as specified in the SCHEDULE OF ACTIVITIES . The 
following will be recorded by the patient in the diary : 
• Results of the 8- point SMBG measurements (on 3 days in the week before the next visit, 
of which 2 should be consec utive days)  
• Mylan’s i nsulin glargine/Lantus® and mealtime insulin doses on days where a 8- point 
SMBG is performed  
• Hypoglycemic  events experienced by the patient   
• Adverse events experienced by the patient  
• Disposable pen and needle - related issues  
The Investigator will instruct the patient on the recording and measurement in detail of these 
assessments and will review the diary as specified in the SCHEDULE OF ACTIVITIES . 
During review the Investigator should assess patient compliance with the trial procedures and 
based on the results of the 8- point  SMBG check if a dose adjustment is required. The entries 
in the patient diary will be transcribed into the eCRF by the Investigator or designee.  
7.5.6.  Hypoglycemia  
Hypoglycemia is a state produced by a lower than normal level of glucose in the blood. This 
may develop, if for example:  
• The patient misses or d elays meals or there is a change in diet  
• The patient takes a higher dose of trial drug than prescribed  
• The patient consumes alcohol  
• The patient does more intense or longer physical exercise or work than normal,  
• The patient is recovering from an injury, operation, fever or other illness, or from 
other forms of stress.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 49 
 7.5.6.1. Classification  
A. Severe Hypoglycemia  
An event is considered as severe hypoglycemia if it requires the assistance of another person 
to actively administer carbohydrate, glucagon, or other resuscitative actions which results in 
neurological recovery, regardless of the availability of a blood glucose measurement. These 
episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. 
Plasma glucose measurements may not be available during such an event, but neurological 
recovery attributable to the restoration of normal plasma glucose is considered sufficient evidence that the event was induced by a low plasma glucose concentration.    
B. Documented Symptomatic Hypoglycemia  
An event during which typical symptoms of hypoglycemia are accompanied by a measured 
plasma glucose concentration ≤70 mg/dL (3.9 mmol/L).  
C. Asymptomatic Hypoglycemia  
An event not accompanied by typical symptoms of hypogl ycemia but with a measured 
plasma glucose concentration ≤70 mg/dL (3.9 mmol/L).  
D. Probab le Symptomatic Hypoglycemia  
Characteristic symptoms of hypoglycemia with no blood glucose level measurement that resolved with food intake, subcutaneous glucagon, or intr avenous glucose.  
E. Relative Hypoglycemia  
An event during which the patient reports any of the typical symptoms of hypoglycemia, and 
interprets the symptoms as indicative of hypoglycemia, but with a measured plasma glucose 
concentration > 70 mg/dL (3.9 mmol/L ). 
F. Nocturnal Hypoglycemia 
Nocturnal hypoglycemia will include hypoglycemia that occurs from the time the patient 
goes to bed at night till the time he or she wakes up. This may include any of the above 5 
types of hypoglycemia.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 50 
 Note:  A diagnosis of severe hypoglycemia as per above classification will always be 
considered as  a serious adverse event. Other hypoglycemic episodes which fulfils ICH 
criteria for seriousness (life -threatening, hospitalization etc.) or represent important med ical 
events based on Investigator’s judgment should also be reported to sponsor within 24 hours. 
7.5.6.2. Identification of Hypoglycemia  
Symptoms of hypoglycemia include but are not limited to the following: palpitations, 
sweating, hunger, nervousness and shakiness, perspiration, dizziness or light –headedness, 
sleepiness, confusion, difficulty speaking, feeling anxious or weak. Neuroglycope nic 
manifestations may include seizure, coma, and even death.  
Patients will be instructed to be alert for signs and symptoms of hypoglycemia; and if 
possible to take glucose meter readings at the time of the episode and to record the details of 
the episode  with any remedial action taken and the blood glucose level (if it was checked) in 
their diary.  
Investigators will instruct the patients on self -management of hypoglycemic episodes. 
Investigators will also instruct patients on remedial actions to be taken during the episodes of severe hypoglycemia. Patients will be encouraged to call the trial site if they experience 
hypoglycemia.  
7.5.6.3. Management of Hypoglycemia  
The following steps are recommended for managing hypoglycemic episodes:  
1. The patient should begin wit h 15 to 20 grams carbohydrate (e.g., 3 -4 teaspoons of 
table sugar dissolved in water, 1 tablespoon of honey, ¾ cup of juice or regular soft 
drink, 3- 4 glucose tablets).  
2. Subsequently, if the glucose level is ≤50 mg/dL, then the patient will be asked to consume 20 to 30 grams carbohydrate (e.g., 4 -6 teaspoons of table sugar dissolved in 
water, 2  tablespoons of honey, 4/5 cup of juice or regular soft drink, 4 -5 glucose 
tablets).  
3. Patient will be asked to recheck blood glucose after 15 minutes and to repeat hypoglycemia treatment if the blood glucose does not return to normal after 15 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 51 
 minutes. If the next meal is more than 1 hour away, patients should follow with 
additional carbohydrate or a snack.  
4. If hypoglycemia persists after the second treatment, patient o r companion should be 
instructed to contact the Investigator.  
It is recommended that the patients always carry some sugar lumps, sweets, biscuits, or sugary fruit juice.  
For an event of severe hypoglycemia the patient can be treated with glucagon (0.5 to  1 mg) 
given intramuscularly or subcutaneously by a person who has received appropriate training, 
or glucose given intravenously by a medical professional. Intravenous glucose can also be 
given if the patient does not respond to glucagon within 10 to 15 mi nutes. Upon regaining 
consciousness administration of oral carbohydrate is recommended in order to prevent a 
relapse.  
Full hypoglycemic episode documentation includes time of occurrence, duration, time of recovery, remedial measures undertaken, recording t he symptoms and plasma glucose / 
SMBG levels at the beginning and end of the episode with time and date, and classification 
in to different subtypes (Refer to section 7.5.6.1).  
7.5.6.4. Reporting of hypoglycemic episodes  
Hypoglycemic events and any associated sympt oms are recorded only on the hypoglycemic 
episodes page of the CRF. Severe hypoglycemia and those episodes meeting any of the ICH 
seriousness criteria (section 8.2.4) are also to be notified as SAEs to the Mylan Global 
Product Safety and Risk Management de partment, as described in section 8.3.2.8; and 
entered on the SAE and AE pages.  
 ADVERSE EVENT  REPORTING  
 Adverse events  
All observed or patient -reported AEs regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as outlined in this section.  The Investigator must pursue and obtain information adequate both to determine the outcome 
of all AEs and to assess whether it meets the criteria for classification as an SAE requiring 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 52 
 immediate notification to Mylan ( the term  “Mylan ” includes Mylan’s designated 
representative) . The Investigator is required to assess causality and should obtain sufficient 
information to determine the causality of all AEs. All AEs will be followed till the event is 
resolved, deemed to be stable, or until the event is found to be due to another known cause 
(concurrent condition or medication) and clinical judgment indicates that further evaluation 
is not warranted with the sponsor concurring with that assessment.  
 Definitions  
8.2.1.  Adverse E vents  
An AE is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product that does not necessarily have a causal 
relationship with the product. An AE can therefore be any unfavorable and unintended sign (including a new, clinically important abnormal laboratory finding), symptom, or disease, 
temporally as sociated with drug administration, whether or not related to the product.  
The above definition covers also cases of  
• Exacerbation of pre -existing diseases or conditions. 
o Pre-existing diseases or conditions (reported at time of randomization in 
medical history) will not be considered AEs unless there is an increase in the frequency or severity, or a change in the quality of the disease or condition.  
Events occurring in patients treated with the active comparator are also considered AEs. An AE will be define d as a treatment -emergent adverse event (TEAE) if the first onset (or 
worsening, in the case of pre -existing disease) is after the first administration of Mylan’s 
insulin glargine or Lantus
® after randomization through follow -up visit or 28 days after last  
dose [for patients that do not have a follow -up visit] .  
8.2.2.  Adverse D rug R eaction  
All noxious and unintended responses to an investigational product related to any dose of the investigation products should be considered adverse drug reactions (ADRs). The phr ase 
“responses to an investigational product” means that a causal relationship between an investigational product and an AE is at least a reasonable possibility. All AEs judged by 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 53 
 either the reporting Investigator or the s ponsor as having a reasonable caus al relationship to 
an investigational product will be designated as ADRs. 
All AEs, with the causal relationship to the trial drug reported as “possible”, “probable” or 
“definite” will be considered ADRs. If the relationship to th e trial  drug is not given, then the 
AE must be treated as if the relationship were “possible.” 
8.2.3.  Unexpected Adverse Event/Adverse Drug Reaction  
An unexpected AE or ADR is defined as one whose nature or severity is not consistent with the applicable reference safety info rmation designa ted for the trial . For example, hepatic 
necrosis would be unexpected (greater severity) if the IB only listed elevated hepatic enzymes or hepatitis. Likewise, cerebral thromboembolism and cerebral vasculitis would be unexpected (greater specificity) if the IB only listed cerebral vascular accidents.  
The reference safety document for Mylan’s i nsulin glargine  is the Investigator’s Brochure. 
The reference safety document s for Lantus
® will be the current US prescribing information  
[7].  
8.2.4.  Serious Adverse Events  
A SAE is any untoward medical occurrence that at any dose:  
• Results in death. 
• Is life -threatening.  
o NOTE: The term “ life-threatening ” in the definition of “serious” refers to an 
event in which the patient was at risk of death at the time of the event . It does 
not refer to an event which hypothetically might have caused death if it were 
more severe.  
• Results in persistent or significant disabilit y/incapacity.  
• Is a congenital anomaly.  
o NOTE: A congenital anomaly in an infant born to a mot her who was exposed 
to the trial drug during pregnancy is considered an SAE. However, a newly 
diagnosed pregnancy in a pat ient that has received the trial  drug is n ot 
considered an SAE unles s it is suspected that the trial drug interacted with a 
contraceptive method and led to the pregnancy. The patient with newly 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 54 
 diagnosed pregnancy will discontinue receiving trial treatment and will be 
followed- up every 3 months until delivery or termination to gather 
information about the outcome of the pregnancy.  
• Is an important medical event.  
o NOTE: Important Medical Event:  Medical and scientific judgment should 
be exercised in deciding whether it is appropriate to consider other  situations 
serious, such as important medical events that may not be immediately life -
threatening or result in death or hospitalization but may jeopardize the patient 
and / or may require intervention to prevent one of the other outcomes listed 
in the def inition above. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse. 
o For this protocol, any cancer, including localized basal cell carcinoma, is considered an important medical event, to be reported as a SAE.  
• Requires inpatient hospitalization or prolongation of existing hospitalization. 
o NOTE: Inpatient hospitalization  is defined as 24 hours in a hospital or an 
overnight stay. Events NOT  to be reported as SAEs are hospitalizations for 
the following:  
 Routine treatment or monitoring of the studied indication, not 
associated with any deterioration in condition.  
 Treatment, which was electi ve or pre -planned, for a pre -existing 
condition that is unrelat ed to the indication under trial  and did not 
worsen.  
 Admission to a hospital or other institution for general care due to social or economic reasons (e.g., no access to local ambulatory medical  care).  
 Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of serious given above and not resulting in hospital admission.  
 
Hospitalization  also does not include the following:  
• Rehabilitation facilities.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 55 
 • Hospice facilities.  
• Respite care (e.g., caregiver relief).  
• Skilled nursing facilities.  
• Nursing homes.  
 
Any non- serious AE that is determined by the medical monitor/sp onsor to be serious (per 
company policy or regulatory requirements) will be communicated to the Investigator for 
reclassification. To assist in the determination of case seriousness further information may be 
requested from the Investigator to provide clarity and understanding of the event in the 
context of the clinical trial.  
 Management of Adverse Ev ents 
AEs or SAEs will be collected from the time the patient signs the informed consent form 
until the end of the  follow -up visit or phone -visit. Pre-existing diseases or conditions 
(reported at  visit 1  in medical history) will not be considered  AEs unless  there is an increase 
in the frequency or severity, or a change in the quality of the disease or condition. A n SAE 
deemed related to the trial  drug by the Investigator in consultation with sponsor will be 
reported even after the follow -up visit if reported by patients. AE s and SAE s would also be 
recorded at phone calls. All SAEs should be immediately ( within 24 hour s) reported as per 
Section  8.3.2.8. 
8.3.1.  Collection  
The Investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an AE or SAE, as described previously. At each visit, the patient 
will be allowed time to spontaneously report any issues since the last visit o r evaluation. The 
Investigator will then monitor and/or ask about or evaluate AEs using non- leading questions, 
such as  
• “How are you feeling?”  
• “Have you experienced any issues since your last visit?”  
• “Have you taken any new medications since your last visit ?” 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 56 
 Any clinically relevant observations made by the Investigator during the visit will also be 
considered AEs. 
The patient’s diary shoul d also be reviewed at each trial  visit for adverse events. At week 0 
visit when trial  diaries are issued, patients will be appropriately educated by the trial designee  
on what constitutes an adverse event and instructed to record adverse events in the trial  diary 
in a timely manner.  
8.3.2.  Evaluation  
8.3.2.1. Severity A ssessmen t of Adverse E vents  
The clinical severity of an AE will be graded using the NCI -CTCAE Criteria Version 4.03. A 
copy of these criteria will be provided to each trial  site. If an AE is not listed in the CTCAE, 
its clinical severity will be classified as follows: 
Table 6: Clinical Severity of Adverse Events  
The Investigator will use the terms defined below  to describe the maximum intensity of the AE.  
Grade 1 –  MILD  Does not interfere with patient's usual function.  
Grade 2 –  MODERATE  Interferes to some extent with patient's usual function.  
Grade 3 –  SEVERE  Interferes significantly with patient's usual function.  
Grade 4 -  LIFE -THREATENING Risk of death at time of event  
Grade 5 –  DEATH  Death related to AE  
 
If an AE is graded 4 or 5 according t o the above criteria, then the AE meets the criteria for an 
SAE and the Investigator should immediately notify the s ponsor or designee as described in 
section  8.3.2.8.  
It is important to distinguish between severe AEs and SAEs. Severity is a classification of 
intensity based on the CTCAE grading or on the above  table , whereas an SAE is an AE that 
meets an y of the regulatory specified criteria required for designation as seriousness 
described in s ection  8.2.4. 
8.3.2.2. Action T aken  
The possible actions taken for an AE are described in  Table 7. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 57 
 Table 7: Action Taken for an Adverse Event  
Dose reduced  The dose regimen was reduced by changing its frequency, strength, or 
amount.  
Dose increased  The dose regimen  was increased by changing its frequency, strength, or 
amount.  
Treatment interrupted  The treatment was temporarily interrupted.  
Treatment withdrawn  The treatment was permanently discontinued.  
Concomitant therapy or procedures  Treatment was needed as a result of the AE (the concomitant treatment should be recorded on the relevant page of the CRF).  
Unknown  Not known, not observed, not recorded, or refused.  
No action taken  The AE did not require any intervention.  
Not applicable  AE occurred after study m edication was permanently withdrawn or 
patient completed the treatment period.  
8.3.2.3. Outcome at the Time of Last O bservation  
The outcome at the time of last observation will be classified as:  
• Recovered/resolved  
• Recovered/resolved with sequelae  
• Recovering/resolving  
• Not recovered/not resolved 
• Fatal*  
• Unknown 
All ongoing AEs without fatal outcome (i.e. did not cause death) will be recorded as not 
recovered/not resolved at the time of death.  
*Only select fatal as an outcome when the AE results in death. If more than one AE is possibly related to the patient’s death, the outcome of death should be indicated for the AE 
which is the most plausible cause of death in the opinion of the Investigator.  
Note:  although “fatal” is usually an event outcome, even ts such as sudden death or 
unexplained death should be reported as SAEs.  
8.3.2.4. Causality Assessment of Adverse E vents  
An Investigator’s causality assessment is the determination of whether there exists a 
reasonable possibility that the investigational product c aused or contributed to an AE. The 
Investigator must make an assessment of the relationship of each AE (serious and 
non-serious) to the trial treatment(s) and record this relationship in the CRF. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 58 
 In addition, if the Investigator determines an AE  or SAE is associated with trial  procedures, 
the Investigator must record this information about the causal relationship in the source 
documents and CRF, as appropriate, and report the assessment in accordance with the 
reporting requirements, as applicable, AE or SAE . 
Factors that need to be considered when making a causality assessment include:  
• Temporal relationship (e.g., time of onset)  
• Clinical and pathological characteristics of the event(s)  
• Pharmacological plausibility  
• Exclusion of confounding factors (medical and medication history)  
• Drug Interactions  
• De-challenge/re- challenge 
• Dose relationship  
 
A suspected relationship (definite, probable, and possible ) between the events and the trial  
medication means, in general, that there are facts (evidence) or arguments to suggest a causal 
relationship. Receipt of additional or clarifying information may warrant reassessment of 
causality. The Investigator is responsible for as sessing relationship of AEs to trial treatment 
in accordance with the following definitions:  
Table 8: Definition of Suspected Relationship between the Events and Trial Medication  
DEFINITELY  Causal relationship is certain  For Example: the temporal relati onship between 
drug exposure and the adverse event (AE) 
onset/course is reasonable, there is a clinically 
compatible response to de -challenge, other causes 
have been eliminated; the event must be definitive 
pharmacologically or phenomenologically, using a 
satisfactory re -challenge procedure if necessary.  
PROBABLY  High degree of certainty for 
causal relationship  For Example: the temporal relationship between 
drug exposure and AE onset/course is reasonable, 
there is a clinically compatible response to de -
challenge (re -challenge is not required), and other 
causes have been eliminated or are unlikely.  
POSSIBLY  Causal relationship is 
uncertain  For Example: the temporal relationship between 
drug exposure and the AE onset/course is 
reasonable or unknown, de -challenge information 
is either unknown or equivocal, and while other 
potential causes may or may not exist, a causal 
relationship to study drug does not appear probable  
UNLIKELY  Not reasonable related For Example: Event or laboratory test abnormality, 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 59 
 although a causal relationship 
cannot be ruled out  with a time to drug intake that makes a relationship 
improbable (but not impossible), or disease or other 
drugs provide plausible explanations  
UNRELATED/NOT 
RELATED  No possible relationship  The temporal relationship between drug exposure 
and the AE onset/course is unreasonable or 
incompatible, or a causal relationship to study drug 
is impossible  
 
If the relationship to the trial treatment(s) is considered to be unlikely or not 
related /unrelated , an alter native suspected etiology should preferably be provided (e.g., 
concomitant medications, intercurrent condition)  wherever applicable and available.  
8.3.2.5. Documentation  
All AEs occurring within the period of observation for the trial must be documented in the 
CRF with the following information; where appropriate (the period of observation for the 
study is described in Section  8.3):  
• AE name or term in standard medical terminology.  
• When the AE first occurred (start date and time); SAE start date is defined as the date 
the AE became serious.  
• When the AE stopped (stop date and time or date and time of last observation if 
ongoing, i.e., recovering or not recovered) . 
• Severity of the AE.  
• Seriousness criteria (hospitalization, death, etc.). 
• Action taken with trial medication as a result of AE.  
• Outcome.  
• Investigator’s opinion regarding the AE relationship to the trial treatments.  
Hypoglycemic events and associated signs/symptoms will only be recorded on the 
hypoglycemic episodes page of the CRF, unless they are SAEs.  
8.3.2.6. Treatment of Adverse E vents  
AEs that occur during the trial will be treated, if necessary, by established standards of care. 
If such treatment constitutes a deviation from the protocol, the reason should be documented 
in the CRF; this can include temporary interruption of trial treatment. The decision about 
whethe r the patient may resume the trial treatment will be made by the s ponsor after 
consultation with the Investigator and/or medical m onitor. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 60 
 8.3.2.7. Follow -up 
Any AE will be followed -up to a satisfactory resolution, until it becomes stable, or until it 
can be explain ed by another known cause (i.e., concurrent condition or medication) and 
clinical judgment indicates that further evaluation is not warranted. All findings relevant to 
the final outcome of an AE must be reported in the patient’s medical record and recorded on 
the appropriate CRF page. 
8.3.2.8. Notification  
For SAEs, the active reporting period to Mylan, begins from the time that the patient 
provides informed consent, which is obtained prior to the pati ent’s participation in the trial, 
i.e., prior to undergoing any t rial-related procedure and/or receiving investigational product, 
through and including the follow up visit . Should an Investigator be made aware of any SAE 
occurring any time after the active reporting period, the SAE must be promptly reported to 
Mylan onl y in case of reasonable causality (i.e. suspected ADR).  
The SAE r eporting form (paper form  only) is to be completed for all serious adverse events, 
signed by the Investigator, and emailed or faxed with supporting documentation (e.g., CRFs, 
hospital records , laboratory reports). Patient identity details (such as but not limited to name 
or clinic/hospital number) must not be visible on SAE forms or any supporting 
documentation provided by the Investigator. These should be “blacked out”, and replaced 
with the site and patient’s trial identification number on every page.  
At that time of first notification, the Investigator/designee should provide the following 
information via the SAE r eport f orm:  
• Protocol number  
• Reporter (trial  site and I nvestigator)  
• Suspected trial treatment  
• Patient’s trial number  
• SAE term  
• The seriousness criteria that were met  
• Investigator’s opinion of the relationship to the trial treatments  
• Severity  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 61 
 • Patient’s age  
• Date of first dose of trial  treatment  
• Date of last dose of trial  treatment, if applicable  
• Start and stop (if applicable) of the event (date and time)  
• A brief description of the event, outcome to date, and any actions taken  
• Concomitant medication at onset of the event  
• Relevant past history information  
• Relevant laborator y test findings  
 
If the initial notification of an SAE is by telephone, within 24  hours of the initial telephone 
notification the Investigator must email the written SAE r eport form that describes the SAE 
to the Mylan Global Product Safety and Risk Managem ent department.  
The Investigator may be requested by Mylan to obtain specific additional follow -up 
information in an expedited fashion. This information collected for SAEs is more detailed 
than that captured on the AE CRF. In general, this will include a description of the SAE in 
sufficient detail to allow for a complete medical assessment of the case and independent 
determination of possible causality. Information on other possible causes of the event, such 
as concomitant  medications and illnesses must be provided. In the case of a patient death, a 
summary of available autopsy findings must be submitted as soon as possible to Mylan.  
Any missing or additional relevant information concerning the SAE should be provided on a follow -up SAE Report Form. Ensure t hat any additional information requested by the 
sponsor or designee about the event, as outlined above (e.g., hospital reports, autopsy report) 
is provided to the sponsor  as soon as it is available.  
Sponsor Contact Information for Immediately Reportable Events  
Email is the preferred method of communication. All SAEs must be notified within 24 hours to:  
Global Product Safety & Risk Management , Mylan  
PV MAIL HUB FOR IMMEDIATE SAFETY REPORTS:  
pvclinical@mylan.com  
In case an acknowledgment is not received within 24 hours, forward via  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 62 
 Fax +1.304.285.6409  
8.3.2.9. Regulatory Reporting 
All AEs, including suspected serious unexpected AEs will be reported in accordance with 
applicable local regulations. The Investigator is required to comply with applicable 
regulations (including local law and guidance) regarding notification to her/his regulatory 
authorities, ethics committees (ECs) and institutions.  
Suspected unexpected serious adverse reactions (SUSARs), SAEs and other cases required by the concerned competent authori ties will be reported by the sponsor or the sponsor’s 
representative to all concerned parties within the prescribed timeframe. The sponsor or representative will also submit periodic safety reports (for e.g., Development Safety Update Reports) as required by international regulations. 
 Special Situations  
The Investigator should report any case of pregnancy within 24 hours via the pregnancy 
report form. Pregnancy exposures must be followed until a final outcome is determined (e.g., 
parturition, spontaneous or  scheduled termination). 
8.4.1.  Pregnancy 
All women of childbearing potential who participate in the trial should be counseled on the 
need to practice adequate birth control and on the importance of  avoiding pregnancy during 
trial participation. Women should be i nstructed to contact the Investigator immediately if 
pregnancy occurs or is suspected.  
Pregnancy testing will b e conducted throughout the trial , as detailed in the schedule of 
assessments. A woman who is found to be pregnant at the  week 0 visit will be excluded from 
the trial. A woman who becomes pregnant during the trial  will be immediately discontinued 
from trial  treatment. Early discontinuation visit assessments should be performed as soon as 
possible after learning of the pregnancy. This information should be captured in the 
pregnancy form and reported to Mylan Global Product Safety and Risk Management within 
24 hours from the time of initial knowledge , even if beyond the closure of the clinical 
database.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 63 
 While pregnancy itself is not considered an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be recorded as an AE or an 
SAE. A spontaneous abortion is always considered to be a SAE and will be reported to the 
sponsor within 24 hours of knowledge of th e event . 
Elective termination (i.e., without medical reasons) of an uncomplicated pregnancy is considered to be an elective procedure and not an AE , nevertheless, Mylan requests that the 
outcome (e.g., elective termination) be reported within 24 hours and sent as a follow -up on 
the Delivery and Infant Follow -up Form).  
The Investigator is also responsible for following up the pregnancy at 3 monthly intervals until delivery or termination, informing the sponsor about its outcome.   
8.4.2.  Overdose, Medication Error s and Other E vents  
Overdose per se  of either study treatment or a concomitant medication will not be reported as 
an AE; unless it is an intentional overdose taken with possible suicidal/self -harming intent. 
Signs, symptoms, and clinical sequelae  associated with intentional overdose are to be 
recorded on the AE CRF page. Dosing and other medication errors are to be recorded as protocol deviations. 
 Abnormal Test Findings   
Abnormal laboratory findings per se (e.g., clinical chemistry, hematology) or  other abnormal 
assessments ( e.g., ECG, X -rays, and vital  signs) are not reported as AEs. However, abnormal 
findings that are deemed clinically significant or are associated with signs and/or symptoms must be recorded as AEs if they meet the definition of an AE (and recorded as an SAE if they 
meet the criteria of being serious). Clinically significant abnormal laboratory or other 
abnormal findings that are detected after trial  drug administration or that are present at 
baseline and worsen foll owing the admi nistration of trial drug are included as AEs (and 
SAEs, if serious). The Investigator should exercise his or her medical judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically significant. Broad guidance  for determining whether an abnormal objective test finding 
should be reported as an AE follows:  
• The test result is associ ated with accompanying symptoms  and/or  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 64 
 • The test result requires additional diagnostic testing o r medical/surgical intervention  
and/or  
• The test result leads to a change in trial  dosing (outside of protocol -stipulated dose 
adjustments)  or discontinuation from the trial , additional concomitant drug treatment, 
or other therapy;  and/or  
• The test result is considered to be an AE  by the Investigator  or sponsor.  
Repeating an abnormal test, in the absence of any of the above conditions, does not constitute 
an AE .   
Any abnormal test result determined by retest to be an error does not require reporting as an 
AE. 
 DATA ANALYSIS/STATIS TICAL METHODS  
 Sample Size Determination    
Approximately 138patients with type 1 diabetes will participate in this trial. Approximately 
69 patients will be randomized to one of the two sequence groups ( Mylan sequence group: 
Mylan’s insulin glargine switch to Lantus® sequence gr oup and switch back to Mylan’s 
insulin glargine or Lantus Sequence Group: Lantus® to Lantus® to Lantus® sequence group) 
in a 1:1 ratio. No replacement of patient will be performed if patient discontinued 
prematurely from the study. For the modified intent -to-treat ( mITT) population, power to 
demonstrate equivalence with ±0.4% limits  will be 90% with 10% patients who don’t have at 
least one baseline and one last period  HbA1c  data. The power is calculated assuming no true 
mean group difference and a 0.61% standard deviation. This standard deviation is based on 
published results for clinical studies with Lantus® [12].  
 General Considerations  
Statistical analysis of this trial will be the responsibility of Mylan or designated clinical 
contract organizations.  
Any change to the data analysis methods will be mentioned in the statistical analysis plan . 
Any additional analysis, and the justification for making the change, will be described in the 
clinical study report. Additional exploratory analyses of the data  will be conducted as 
deemed appropriate.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 65 
 For the statistical analysis , baseline is visit 1, which includes the post study measurements of 
the main study MYL -GAI-3001.  
9.2.1.  Primary End Point  
The HbA1c difference  of change from baseline between two periods at 12 weeks  from week 
36.  If week  36 HbA1c is missing then last non- missing values from period 3 will be used.      
9.2.2.  Study Population  
The primary analysis will be based on the  mITT population.  
• The ITT population includes all randomized patients (including pati ents who receive 
incorrect treatment, do not complete the trial or do not comply with the protocol or 
used prohibited medication) and have baseline ( week 0 visit) and at least one post -
baseline value. ITT population will be used for secondary variable anal yses.  
• The mITT population includes all randomized patients (including patients who 
receive incorrect treatment, do not complete the trial or do not comply with the 
protocol or used prohibited medication) and have  at least one baseline (week 0 visit) 
HbA1c value and one post -baseline HbA1c value at treatment period 3. The mITT 
will be used for primary analysis.  
• Per Protocol (PP) population. The PP population includes patients who complete  at 
least one baseline and one period 3 values and do not have protocol  violations that 
impact the primary outcome . The subjects excluded from the PP population will be 
identified before database lock .  PP population will be used for sensitivity analysis for 
primary variable.   
 
• The safety population includes patients who take  at least one dose of the trial 
medication. For safety analyses, patients will be categorized according to the 
treatment that they actually received. Safety population will be mainly used for safety population. 
9.2.3.  Handling Missing Values  
No missing data will be imputed  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 66 
 9.2.4.  Pooling  
No data pooling will be performed . 
9.2.5.  Multiplicity Adjustment  
No adjustment for multiplicity will be performed.  
9.2.6.  Statistical Methods  
For primary endpoint analysis, equivalence for efficacy will be supported if the two sided 
95% confidence interval for the difference of mean between two sequence groups ( endpoint 
of change from baseline of Mylan sequence group minus endpoint of  Lantus  sequence) for 
HbA1c is within ± 0.4%. 
For sequ ence comparison analysis for continuous variables, analysis of covariance 
(ANCOVA) will be used (unless otherwise specified) with the terms of geographic region 
and sequence group as fixed effects and baseline value as covariate in the model.  For 
continuous variables with more than one measurements within period, a  repeated measures 
analysis employing a restricted maximum likelihood (REML) -based, mixed -effects model 
approach (MMRM) will be used for treatment comparison.  For continuous variables without 
baseline value, analysis of variance will be used (unless otherwise specified). The baseline 
values for this study are the measurements after 52 weeks in MY L-GAI-3001. Paired t -test 
will be performed for change from baseline comparisons for each post -baseline visits . For 
categorical data analyses, Fisher’s exact or C hi-squared tests will be used. All tests of 
treatment effects will be conducted at a two -sided alpha level of 0.05 or with 2- sided 95% 
confidence intervals.  
 Patient Disposition  
The percent of randomized patients who completed the trial or discontinue early will be summarized for each sequence group. The comparison of patient discontinuations across 
sequence groups will be performed using the Fisher’s exact test.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 67 
 
 Protocol Violati on 
A list of significant protocol violations will be provided. A summary by sequence group at 
each period will also be provided, and sequence group comparison will be performed using 
the Fisher’s exact test. Other protocol deviations will be listed in the appendices.  
 Patient Characteristics  
Patient characteristics will be obtained at the week 0 visit; and will be listed and summarized by sequence group, and overall. The summaries will include descriptive statistics for 
continuous and categorical measures. P arameters will be compared by sequence group using 
a two sample t -test for continuous measures. A Pearson's chi -square test or Fisher’s exact test 
will be used to test categorical measures. Patient characteristics include but are not limited to: 
age, gende r, origin, race, weight, body mass index, duration of diabetes, baseline HbA1c and 
baseline fasting plasma glucose.  
 Concomitant Medication  
Categorical use of concomitant medication taken by at least 10% patient and overall will be summarized by treatment. All concomitant medications used will be listed. Sequence groups 
will be compared by Chi -squared test.  
 Primary Efficacy Analysis  
The primary endpoint is change from baseline in HbA1c  value  at 36  weeks. ANCOVA will 
be performed; and the model will include region and sequence group as fixed effect and 
baseline value (52 weeks in MYL -GAI-3001) as covariate using m ITT population. The 
ANCOVA will produce a 95% confidence interval for the difference between two treatment 
sequence groups for mean change from baseline  HbA1c  at endpoint . Equivalence  of Mylan’s 
insulin glargine to Lantus® will be established if the 95% confidence interval is within ± 0.4%  
equivalence limits.  Descriptive statistical summaries for actual measurements and change 
from baseline will be dis played by visit and endpoint for each sequence group using ITT 
population.   
In order to check the sensitivity of the result, primary analysis will be also performed on PP 
population using same model mentioned above.  
 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 68 
 
 Secondary Efficacy Analyses  
In addition to the primary efficacy analysis for HbA1c, the following efficacy measures (both 
actual and change in values) will be summarized for each sequence at each post -baseline 
visits . Sequences will be compared using the MMRM ANC OVA model  (similar to HbA1c 
analysis) . The dependent variable will be the differences of change from baseline between 
two periods. The MMRM model will include the fixed, categorical effect of region and 
sequence group, visit, sequence  group- by-visit interaction and the other  as fixed  effect terms 
region, and baseline value as covariates .  
Descriptive statistical summaries for actual values and change from baseline will be 
displayed by visit and endpoint for each sequence group. ITT population will be applied to 
secondary efficacy anal yses.  
• Fasting plasma glucose;  
• SMBG value: individual pre -meal, individual post -meal, individual 2- hour excursion 
after meal, bedtime, overall (average) pre- meal, overall post -meal, overall excursion, 
4-point average (pre -meal + bedtime), and daily average;   
• Daily prandial insulin, basal insulin, and total insulin dose (U/kg)  for days of 8- point 
profiles.  
 Safety Analyses  
Safety analysis will be based on safety population which includes all enrolled patient s who 
take at least one dose of trial  medication . 
9.9.1.  Treatment Exposure  
Total treatment duration days will be summarized for each sequence arm. The sequence 
group will be compared using t -test.  
9.9.2.  Immu nogenicity Profiles Analyses  
Continuous immunogenicity variables such as cross -reacting antibodies percent binding will 
be analyzed using the MMRM ANC OVA model , similar to the primary  and secondary  
efficacy analyses.  The model will include the fixed, categorical effect of region and 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 69 
 sequence group, visit, sequence  group- by-visit interaction and the other  as fixed  effect terms 
region, and baseline value as covariates .  The p -value for sequence difference and 95% 
confidence interval will be constructed. If the normal distribution assumption is severely 
violated, then non- parametric analysis will be performed using Wilcoxon rank- sum test for 
sequence comparison.  
Descriptive statistical summaries for actual measurements and change from baseline will be 
displayed by visit for each sequence group. For categorical variables such as ADA positive 
and negative, frequency table will be presented by visit for each period for each sequence.  
Fisher’s exact test will be used for sequence comparison by visit.  
9.9.3.  Hypoglyc emia Analyses  
Hypoglycemia rate per patient per 30 days will be analyzed using MMRM ANC OVA model 
secondary  for sequence group comparison. T he model will include the fixed, categorical 
effect of region and sequence group, visit, sequence group- by-visit inte raction and the other  
as fixed effect terms region, and baseline value as covariates .  The p -value for sequence 
difference and 95% confidence interval will be constructed .  The rate per patient per 30 days 
calculated between two visits is defined as total number of episodes between two visits divided by the number of days between the visits, multiplied by 30 days. This rate will also 
be calculated per patient for nocturnal hypoglycemia episodes. In case the normal 
distribution assumption is severely violate d, then non- parametric analysis will be performed 
using Wilcoxon rank- sum test for sequence group comparison.  
Incidence of all hypoglycemic episodes and nocturnal hypoglycemic episodes will be 
presented by sequence group by visit for each period. The incidence of hypoglycemic episodes during visit time period on treatment is defined as the incidence of patients with at 
least one hypoglycemic episode occurring within that period of time. Fisher’s exact test will 
be used for sequence comparison by visit. 
Listings of hypoglycemic episodes and severe hypoglycemic episodes will be presented by 
visit for each patient. If a sufficient number of severe hypoglycemic episodes are reported, then incidence summaries similar to the incidence of hypoglycemic episodes will be 
included. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 70 
 9.9.4.  Adverse Event Analyses  
The evaluation of adverse events will include assessments of TEAEs and SAEs. 
The incidence of TEAEs will be summarized to include only one occurrence of a PT per 
patient per treatment period. If a patient reports multip le occurrences of the same PT and 
treatment period, then that PT will only be counted once. As with the PT, if a patient reports multiple TEAEs within the same SOC and treatment period, that SOC will only be counted 
once. Incidence of TEAEs will be present ed by  treatment sequence.  The incidence of TEAE 
by severity and relation to study drug will also be summarized by treatment sequence. The 
incidence of both local and systemic allergic reaction -related TEAEs will be also 
summarized separately by SOC and treatment period for each sequence group. Fisher’s exact 
test will be used f or sequence comparison by visits . 
9.9.5.  Vital Sign s 
Change from baseline for vital signs will be analyzed using MMRM method similar to the 
secondary  efficacy variables the ANC OVA model  for sequence group comparison. The 
model will include the fixed, categorical effect of region and sequence group, visit, sequence group -by-visit interaction and the other  as fixed effect terms region, and baseline value as 
covariates.   The p -value for seq uence difference and 95% confidence interval will be 
constructed using the same model  for the combined periods.  The summary statistics 
including actual measurement and change from baseline will be displayed at each visit for each sequence group.  
9.9.6.  Laboratory Measurement  
Change from baseline for laboratory evaluations will be analyzed using similar ANCOVA model  for primary analysis  for treatment sequence comparison . The summary statistics 
including actual measurement and change from baseline will be displaye d at each visit for 
each sequence group.  
9.9.7.  ECG  
Summary of frequency table of percentage of patients in categories such as abnormal/non-clinically significant and abnormal/clinically significant will be presented by visit and 
sequence group.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 71 
 9.9.8.  Device Safety A ssessment  
The total incidence of device- related safety events will be summarized with each sequence 
arms , per treatment arm,  at each period both for device -related TEAEs and for events related 
to device complaints or failures . 
 Subgroup Analyses  
No subgroup analysis will be planned.  
 QUALITY CONTROL AND QUALITY ASSURANCE  
This trial will be audited  by the sponsor or sponsor’s designee s to check c ompliance with 
GCP guidelines. The sponsor or designee may conduct audits on any selected trial  sites, 
requirin g access to patient notes, trial documentation, and facilities or  laboratories used for 
the trial. 
Monitoring and auditing procedures are described in the following sections. 
 Study Monitoring  
Before the start of the trial at a study site, an initiation visit or phone call will be conducted 
by the monitor. During the trial the monitor will visit the site to review the implementation of 
the center’s processes associated with  but not limited to : 
• Completion, consistency, and accuracy of entries in the eCRFs  
• Sour ce data verification  
• Progress of enrollment  
• Adherence to the protocol and to GCP  
• Proper storage, dis pensing, and accounting of trial  medication as specified in the 
protocol  
The Investigator and key site personnel must be available to assist the monitor during these 
visits.  
The Investigator must maintain source documents  for each patient in the trial , as well as other 
trial documents, as specified in section 11.2. No patient identification information will leave 
the trial center.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 72 
 In the case of electronic health records , the Investigator must give the monitor access to all 
relevant source documents to confirm consistency with the eCRF entries. Monitoring will be 
performed according to the monitoring plan for this trial.  
The Investigator (or his or her staff) is responsible for completing the eCRFs and the monitor 
is responsible for reviewing them and for clarifying and assisting in resolving an y data 
queries.  
 Audits and Inspections  
Quality assurance personnel  may conduct audit s to evaluate compliance with the principles 
of GCP.  
If an inspection is requested by a regulatory authority  or competent authority (during the trial 
or after its completion) , the Investigator must inform the sponsor immediately.  
If an audit or inspection occurs, the Investigator and institution agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and the 
time of his/her  staff to the auditor/inspector to discuss findings and any relevant issues. 
Participation as a n Investigator in this trial implies acceptance of potential inspection by 
regulatory authorities.  
 DATA HANDLING AND RE CORD KEEPING  
 Electronic Case Report Forms  
Before a trial is initiated the sponsor’s representative will review the protocol and eCRF with the Investigators and the study staff.  
By signing the Investigator’s Agreement, the Investigator agrees to maintain accurate eCRFs 
and source documentation as part of the case histories for all patients who sign an ICF.  
Investigat or sites will be provided with access to the eCRF system , which has been fully 
validated and conforms to 21 Code of Federal Regulations Part 11 requirements. The site 
staff will be train ed on the use of the eCRF including trial  specific details before they are 
able to enter the trial  data. Investigational staff will not be given access to the eCRF  until 
they have been trained and assessed as competent to use the system.  
Designated investigational staff will enter all requested information  (including 
information entered into the diaries by the patients ) required b y the protocol into the eCRFs. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 73 
 To ensure data accuracy, eCRF data for individual patient visits  should be completed as soon 
as possible after the visit. Automated data validation software will check for data 
discrepancies in the eCRFs and, by generating appropriate error messages, allow 
modification or verification of the entered data by the investigational staff. The monitor  will 
perform data verification and will  document this electronically  in the eCRFs . The 
Investigator or designee must certify that data are complete and accurate within the system 
by providing electronic approval of the eCRF pages. A reasonable explanation  must be given 
by the Investigator or authorized staff for all missing data. Queries will be sent to the 
investigational site  through the eCRF  system . Designated Investigator site staff are required 
to respond to the queries and make any necessary changes to the data.  
Concomitant medications entered into the database will be coded using the WHO Drug 
Dictionary , which employs the Anatomical Therapeutic Chemical classification system. 
Medical history or current medical conditio ns and AEs will be coded using MedDRA 
terminology.  
Corresponding source documentation must support all information recorded in the eCRF . 
Examples of acceptable source documentation include, but are not limited to, hospital 
records, clinic and office charts , laboratory notes, and recorded data from automated 
instruments, memoranda, and pharmacy dispensing records.  
Clinical laboratory data required by the protocol will be electronically transferred from the 
central laboratory to the sponsor or designee. Labo ratory resul ts will be provided to the trial  
site and should be retained with each patient’s source data.   
 Record Retention  
Data on patients collected on eCRFs will be documented in an anonymous fashion and the 
patient will only be identified by the patie nt number.  
At the end of the trial, the Investigator will receive a copy of the data entered into the eCRF 
for his or her site. The Investigator will retain the study documents for at least 15 years or as 
per local laws (whichever is longer). At the end of  that period, the Investigator shall notify 
the sponsor in writing of her/his intent to destroy all such material. The sponsor shall have 
30 days to respond to the Investigator’s notice; the sponsor may request that the site retain s 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 74 
 the materials for a longer duration, at the sponsor’s expense. Source documents should be 
retained according to local laws and institution requirements .   
 Data Confidentiality  
All data generated from the trial  will be regarded as confidential. The monitor(s), the 
auditor(s), the IRB/IEC, and the regulatory authority( ies) will be granted direct access to the 
patient’s original medical r ecords for verification of trial  procedures and/or data, without 
violating th e confidentiality of the patient, to the extent permitted by the applicable laws and 
regulations and that, by signing a written ICF, the patient or the patient's legally acceptable 
representative will be authorizing such access. The records identifying the  patient will be 
kept confidential and, to the extent permitted by the applicable laws and/or regulations, will 
not be made publicly available. If the results of the trial are published, the patient's identity 
will remain confidential. All data (whether me dical or laboratory) gene rated in the course of 
the trial will remain the property of the sponsor.  
 Source Data Access  
Direct access to source data or document s will be permitted during trial- related monitoring, 
audits, IRB/IEC  review and regulatory inspe ction(s). 
 Responsibilities Related to Devices  
11.5.1.  Investigator Records and Reports ( See Appendix V - Letter of Approval of Pen Use 
by the Investigator ) 
According to the 21 CFR 812.140 and 150 a participating Investigator shall maintain the 
following accurate, complete, and current records relating to the Investigator's participation 
in an investigation:  
• Record of receipt, use or disposition of a device that relate to:  
 The type and quantity of the device, the dates of its receipt, and the batch number 
or code mark  
 The names of all persons who received, used, or disposed of each device  
 Why and how many units of the device have been returned to the sponsor, 
repaired, or otherwise disposed of  
• Documents evidencing informed consent and, for any use of a device by the  
Investigator without informed consent, any written concurrence of a licensed 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 75 
 physician and a brief description of the circumstances justifying the f ailure to obtain 
informed consent. The case history for each patient  shall document that informed 
consent was obtained pr ior to participation in the trial. 
• An Investigator shall prepare and submit the following complete, accurate, and timely 
reports:  
 An Investigator shall submit to the sponsor and to the reviewing IRB a report of 
any unanticipated adverse device effect occurring during an investigation as soon 
as possible, but in no event later than 10 working days after the Investigator first 
learns of the  effect.  
 An Investigator shall report to the sponsor, within 5 working days, a withdrawal 
of approval by the reviewing IRB of the Investigator's part of an investigation. 
 If an I nvestigator uses a device without obtaining informed consent, the 
Investigator  shall report such use to the sponsor and the reviewing IRB within 5 
working days after the use occurs.  
 An Investigator shall, upon request by a reviewing IRB or FDA, provide accurate, 
complete, and current information about any aspect of the investigation. 
Please see Appendix V  for instructions regarding the prohibition of promotion and other 
practices and a format for the letter of approval of pen use by the Investigator (for US sites 
only).  
 PROTOCOL AMENDMENTS , DEVIATIONS  AND COMPLIANCE  
Investigators should ascertain that they will apply due diligence to avoid protocol deviations. 
No waivers to the protocol will be given by the sponsor.  
All significant protocol deviations will be recorded and reported in the CSR  main body . 
These will include variable deviations , for example : 
1. Patient not  meeting selection criteria but still included in the study  
2. Patient continued in the study despite meeting study discontinuation criteria  
3. Failure to perform tests or procedures which will impact the interpretation of key  
endpoints (e.g. safety, efficacy, immunogenicity endpoints) of the study  
4. Patient not following treatment regimen mentioned in the protocol  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 76 
 5. Patient taking medications which are prohibited by the protocol, or can have impact 
on key endpoints of the study  
6. GCP not followed. 
With respect to inadequate documentation or conduct of SMBG, the following rules will be 
followed to determine deviations : 
• In any given week, if there are missing values for SMBG AND the Investigator 
documents that the patient is non- compli ant, a protocol deviation (for that visit) will 
be recorded; and listed in the main body of the CSR (as well as in the CSR appendices) . 
• In any given week, if there are missing SMBG values without accompanying documentation of non -compliance by the Investig ator, a protocol deviation (for that 
visit) will be recorded; but listed only in the CSR appendices, and not in the main body.  
Any change to the protocol can only be made in the form of a written amendment to the trial protocol. Depending on the local regulatory requirements, the amendment must be approved 
by the national authority and/or IEC/IRB before the amendment is implemented.  
Only amendments that are required for patient safety may be implemented prior to IEC/IRB 
approval.  
Notwithstanding the need f or approval of formal protocol amendments, the Investigator is 
expected to take any immediate action required for the safety of an y patient included in this 
trial, even if this action represents a violation of the protocol. In such cases, the sponsor 
shoul d be notified of this action immediately . 
 ETHICS  
 Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Before the start of the study, the protocol, written ICF, and/or other appropriate documents will be submitted to and approved by the IRB/ IEC and/or the competent authorities, in 
accordance with local legal requirements. The study will not commence until written confirmation of their approval has been received by the sponsor or designee. No clinical 
supplies may be sent to the study sites until the relevant approvals from the IRB/ IEC and 
competent authorities have been obtained.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 77 
 No patient may undergo any procedure solely for determ ining eligibility for this trial until the 
Investigator has received written a pproval by the IRB/ IEC and the regulatory authority . 
 Ethical Conduct of the Study  
The trial  will be conducted in accordance with legal and regulatory requirements, as well as 
the general principles set forth in the International Ethical Guidelines for Biomedical 
Research Involving Human Subject  (Council for International Organizations of Medical 
Sciences 2002), Guidelines  for GCP  (ICH 1996), and the Declaration of Helsinki (World 
Medical Association 2013). In addition, the trial  will be conducted in accordance with the 
protocol, and appl icable local regulatory requirements and laws.  
 Patient  Information and Consent  
All parties will ensure pro tection of patients ’ personal information. Patient  names will not be 
included on any forms, reports, publications, or in any other disclosures  to the sponsor . 
The informed consent document must be in compliance with ICH GCP, local regulatory 
requirements, and legal requirements. The informed consent document  to be used in this trial, 
and any changes mad e during the course of the trial , must be prospectively approve d by both 
the IRB/IEC and the sponsor or  designee before use.   
According to the Declaration of Helsinki, and ICH-GCP, patients must provide their written 
informed consent prior t o enrollment in a clinical trial and before any protocol -specified 
procedures are performed. Patients must declare their consent by personally signing and dating the informed consent form (ICF).  
The patient will also be informed that if s he/he wishes to wi thdraw ( see section  6.2) at any 
time during the trial this will not have any negative consequences to further treatment at the 
investigational site.  
 DEFINITION OF END OF  TRIAL  
The end of this trial  is defined as the date of the last visit of the last pa tient participating in 
the trial (last patient out or last patient last visit). Within 90 days of the end of the clinical 
trial the sponsor or designee will notify the ECs and regulatory authorities on the completion 
/ termination of the trial as required according to law and regulation.   
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 78 
 
 End of Trial in a Member State  
End of t rial in a Member State of the European Union is defined as the time at which it is 
deemed that sufficient patient s have been r ecruited and have completed the trial  as stated in 
the regulatory application (i .e., clinical trial application [ CTA ]) and ethics ap plication in the 
Member State) . Poor recruitment (recruiting less than the anticipated number in the CTA) by 
a Member State is not a reason for premature termination but is considered a normal 
conclusion to the trial  in that Member State.  
 End of Trial in all Other Participating Countries   
End of t rial in all other participating countries is defined the date and time of the l ast patient  
(patient) last visit.  
 SPONSOR DISCONTINUAT ION CRITERIA 
The sponsor is entitled to terminate the study:  
• In case there is evidence that the safety of the trial participants is no longer assured.  
• In case the 3001 study interim analysis affects the curren t favorable patient risk 
benefit relationship. 
Should this be necessary, the sponsor will promptly notify the Investigators; and the 
Investigators will be informed of the procedures to be followed to assure that adequate 
consideration is given to the protection of the patient’s  interest .  
Pursuant to law and regulation, the sponsor or Investigator will notify IRB/IECs and 
regulatory authoritie s within 15 days of premature termination of the trial, clearly explaining 
the reasons for premature termination. After notification, the Investigator must contact all 
participating patient s and the hospital pharmacy (if applicable) within 30 days . Trial sites 
may be asked to have all patients curr ently participating in the trial to complete all 
assessments for an early termination visit. As directed by the sponsor , all trial materials must 
be collected and all eCRFs completed as far as possible.  
A specific site may be terminated for unsatisfactory patient enrolment (as long as there are no 
active recruited patients) , insufficient quality , or for improper data recording.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 79 
 IRB/IECs and r egulatory authorities  may also terminate the trial prematurely for any reason 
and at any time following  consultation with the sponsor . A decision to prematurely  terminate 
the trial is binding on all I nvestigators.  
 PUBLICATION OF STUDY RESULTS  
Information generated by the trial  is the property of the sponsor. Publication or other public 
presentation of data resulting from this trial requires prior review and written approval of the 
sponsor .  
 Communication of Study R esults  
This trial will be r egistered on ClinicalTrials.gov , the EudraCT database and in other trial 
registries as deemed appropriate. The basic results will be posted at  www.clinicaltrials.gov in 
a tabular format with in a year from the end of the trial  (as defined in the preceding sections)  
or upon finalization of the CSR , whichever occurs later . 
The trial  results will be documented in a clinical study report (CSR), in an ICH  E3-compliant 
format. A copy of the final report, duly checked for correctness, completeness, integrity, and 
accurate represen tation of data and interpretation of  trial outcome, will be issued to 
Investigator s and counter -signed by the global coordinating Investigator ; as per the sponsor’s 
SOPs.  
 Publications by Investigators  
For all publications relating to the trial, institutio ns will comply with recognized ethical 
standards concerning publications and authorship, including Section II -  “Ethical 
Considerations in the Conduct and Reporting of Research”  of the Uniform Requirements for 
Manuscripts Submitted to Biomedical 
Journals, http://www.icmje.org/index.html#authorship, established by the International 
Committee of Medical Journal Editors.  
Data from individual trial sites mus t not be published separately. It is agre ed that the results 
of the trial will not be submitted for abstract, presentation, poster exhibition or publication by 
the Investigator until the sponsor has reviewed and commented on the presentation or 
manuscript for publication. Abstracts, manuscripts, and presentation materials shoul d be 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 80 
 provided to the sponsor  for review and approval at least 30 days prior to the relevant 
submission deadline. 
 REFERENCES  
1. de Graaff LC, Smit JW, Radder JK. Prevalence and clinical significance of 
organ- specific autoantibodies in type 1 diabetes mellitus. Neth J Med . 2007; 
65(7):235- 247. 
2. Diabetes Control and Complications Trial Research Group: The effect of intensive 
treatment of diabetes on the development and progression of long -term complication 
in ins ulin dependent diabetes mellitus. N Engl J Med. 1993;329(14):977- 986. 
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. 
N Engl  J Med . 1993;329(5):304- 309. 
4. American Diabetes Association. Standards of Medical Care in Diabetes -2014. 
Diabetes Care . 2014; 37(S1):S14- S80. 
5. EMEA. Annex To Guideline On Similar Biological Medicinal Products Containing Biotechnology -Derived Proteins As Active Substance: No n-Clinical And Clinical 
Issues:  Guidance On Similar Medicinal Products Containing Recombinant Human 
Soluble Insulin (EMEA/CHMP/BMWP/32775/2005). 2006 
6. Investigator ’s Brochure for Mylan ’s Insulin glargine  (available upon request).  
7. Lantus
® US Prescribing Information. Sanofi -Aventis, 2009.  
8. Streja D. Can continuous glucose monitoring provide objective documentation of hypoglycemia unawareness? Endocrine Practice. 2005;11:83- 90. 
9. Janssen MJ, Snoek FJ, Heine RJ. Assessing Impaired Hypoglycemia Awareness in Type 1 Diabetes. Diabetes Care . 2000; 23:529–532.  
10. Summary of Product Characteristics. Humalog
® EPAR. Last updated on 11 May 
2011; accessed on 10 July 2013. 
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000088/WC500050332.pdf).  
11. Humalog® US Prescribing Information. Eli Lilly, 2013. 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 81 
 12. Clinical trial.gov. available 
at https://clinicaltrials.gov/ct2/results?term=lantus+ed ition&Search=Search . Accessed 
on 23 Sep 2015.  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 82 
 
 APPENDICES  
Appendix  Title  
I Questionnaire to Assess Hypoglycemia Unawareness  
II Suggested General Guidance for Insulin Dose Titration 
III 4- and/or 8-point  Glucose Estimation Time Points  
IV Sample Patient Diary  Information 
V Letter of Approval of Pen Use by the Investigator  (for US sites only)  
  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 83 
 Appendix I -  Questionnaire to Assess Hypoglycemia Unawareness   
Please circle only one answer for each question.  
1. Have you lost the ability to experience symptoms such as sweating, shaking, 
palpitations, light- headedness, or nervousness when your blood sugar is low?  
  No / Yes  
2. To what extent can you recognize low blood sugar based on symptoms?  
  Never / Seldom / Sometimes / Often  / Always ["Never," "Seldom," or 
"Sometimes" = Yes]  
3. Below which level do you feel that your blood sugar is low?  
  65 / 60 / 55 / 50 / 45 [55 or below = Yes]  
4. During the past year, did you have any low blood sugar episode associated with 
confusion for whic h you required assistance from another person?  
  No / Once / More than once ["More than once" = Yes]  
5. During the past year, did you have any low blood sugar episode for which you 
required intervention from paramedics, an emergency department visit, or an injection 
of glucagon by another person?  
No / Yes  
Diagnosis of Hypoglycemia Unawareness (HUN)  
Patients will be considered to have HUN if 3 of the 5 questions were scored "yes."  
References: [ 8,9]. 
  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 84 
 Appendix II -  Suggested Guidance for Insulin Dose Titration  
Lowest fasting capillary blood glucose 
(pre- breakfast) value for 3 days  Adjust basal insulin dose (U per dose) 
(Lantus® or Mylan ’s insulin glargine ) 
>270 mg/dL  + 6 U  
181-270 mg/dL  + 4 U  
151-180 mg/dL  + 2 U  
131-150 mg/dL  + 1 U  
71-130 mg/dL (Target level)  Maintain Dose  
56-70 mg/dL  -2 U 
<56 mg/dL  -4 U 
 
Lowest post -prandial capillary blood  
glucose value (2 hour post food) for 3 days  Adjust mealtime  insulin dose (U per dose) 
(Insulin lispro ) 
>270 mg/dL  + 6 U  
201-270 mg/dL  + 4 U  
180- 200 mg/dL  + 2 U  
< 180 mg/dL (Target level)  Maintain Dose  
 
Comments:  
o Titration should be performed first for the basal insulin. For elevated fasting 
pre-breakfast glucose levels, adjust only the basal insulin dose. 
o Once basal insulin level has been titrated to optimum, then mealtime  insulin should 
be titrated.  
o Post-prandial glucose levels are estimated 2 hours after the start of the respective food 
intake.  
o Apart from glucose levels, the dose of mealtime  insulin should be guided by expected 
carbohydrate content of the next meal, and expected level o f physical activity within 
next 4 -6 hours. If meal is skipped, the dose should be skipped.  
o The target should be the lower limit of the range mentioned above, so that the final 
value will remain in  the expected range.   
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 85 
 Appendix III -  4-Point and/or 8- Point  Glucose Estimation Time Points  
Time of the day  Specific point ( 8-point ) Specific point (4 -point)  
Fasting Before breakfast  1 1 
2 hours after breakfast  2  
Before lunch  3 2 
2 hours after lunch  4  
Before dinner  5 3 
2 hours after dinner  6  
Just before sleep  7 4 
At 3±1 AM  8  
 
Comments:  
o Specific days on which the SMBG need to be estimated is as mentioned in the 
Assessment Schedule . 
o On all days in which SMBG is not mandated by protocol, patients will be advised to 
self-monitor blood glucose 4 times a day as per standard of care in type 1 diabetes.  
o The 8th point time can be adapted for patients on night shift ( in discussion with the 
Investigator ) to approximately 4 hours after going to bed. 
 
  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 86 
 Appendix I V - Sample Pa tient Diary Information  
• Trial, site and patient identification information  
• Results of 8- point SMBGs performed as per protocol  
• Insulin dose information on days where 8- point SMBGs are performed 
• Details of hypoglycemic events  
• Details of untoward experiences (AEs)   
• Details of problems with the disposable pens or needles 
  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 87 
 Appendix V -  Letter of Approval of Pen Use by the Investigator  (for US Sites only)  
Prohibition of Promotion and Other Practices  
According to the 21 CFR  812.7, an Investigator or any person acting for or on behalf of a 
sponsor or Investigator shall not:  
• Promote or test market an investigational device, until after FDA has approved the 
device for commercial distribution.  
• Commercialize an investigational device by char ging the patients or investigators for 
a device a price larger than that necessary to recover costs of manufacture, research, 
development, and handling.  
• Unduly prolong an investigation. If data developed by the investigation indicate in the 
case of a class  III device that premarket approval cannot be justified or in the case of 
a class II device that it will not comply with an applicable performance standard or an 
amendment to that standard, the sponsor shall promptly terminate the investigation.  
• Represent that an investigational device is safe or effective for the purposes for which 
it is being investigated.  
  
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 88 
 The format below should be followed for the letter of approval.  
The protocol identification code for the study in the IND   
Name and address of the Investigator   
The name and address of the sub -Investigators who will be 
assisting the I nvestigator in the conduct of the study   
The name and address of the medical school, hospital or other 
research facility where the clinical investigations will be 
conducted  
  
The name and address of the clinical laboratory facilities to 
be used in the study  
  
The name and address of the institutional review board that is 
responsible for review and approval of the study  
  
1. I have gone through the protocol and agree to conduct the study as mentioned in the protocol  
2. I have sufficient education, training and experience in the clinical investigation of the drug 
using the new device.  
3. I shall maintain the following accurate, complete, and current records relating to the my 
participation in the investigation:  
• Record of receipt, use or disposition of a device that relate to:  
o The type and quantity of the device, the dates of its receipt, and the batch number or code 
mark.  
o The names of all persons who received, used, or disposed of each device.  
o Why and how many units of the device have been returned to the sponsor, repaired, or 
otherwise disposed of.  
• Documents evidencing informed consent and, for any use of a device by the I nvestigator 
without informed consent, any written concurr ence of a licensed physician and a brief 
description of the circumstances justifying the failure to obtain informed consent. The case 
history for each individual shall document that informed consent was obtained prior to 
participation in the study. 
4. I shall  prepare and submit the following complete, accurate, and timely reports:  
o I shall submit to the sponsor and to the reviewing IRB a report of any unanticipated 
adverse device effect occurring during an investigation as soon as possible, but in no 
event late r than 10 working days after the I nvestigator first learns of the effect.  
o I shall report to the sponsor, within 5 working days, a withdrawal of approval by the 
reviewing IRB of my part of an investigation. 
o If I use a device without obtaining consent form, I shall report such use to the sponsor 
and the reviewing IRB within 5 working days after the use occurs.  
o I shall, upon request by a reviewing IRB or FDA, provide accurate, complete, and current information about any aspect of the investigation.  
5. I shall not : 
• Promote or test market an investigational device, until after FDA has approved the device for 
commercial distribution.  
• Commercialize an investigational device by charging the patient s or I nvestigators for a device 
a price larger than that necessary to re cover costs of manufacture, research, development, and 
handling. 
• Unduly prolong an investigation. If data developed by the investigation indicate in the case of 
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 89 
 a class III device that premarket approval cannot be justified or in the case of a class II dev ice 
that it will not comply with an applicable performance standard or an amendment to that 
standard, the sponsor shall promptly terminate the investigation.  
• Represent that an investigational device is safe or effective for the purposes for which it is 
being investigated.  
 
The details of Mylan ’s insulin glargine  pen have been provided to me. I have gone through the 
detailed literature, label, and the user information. I am aware that the disposable pen planned for the 
study is not yet approved by FDA. I approve the use of the Mylan  non-cleared, disposable pen 
injector for this study based on the device posing no significant risk to the patient.  
 
 
  Signature and date  
  
       
     
Insulin Glargine  MYL -1501D -3003  
Final Protocol  V2.0  06-May-2016  
 
 
MYLAN CONFIDENTIAL  
Page 90 
 INVESTIGATOR AGREEME NT PAGE  
PROTOCO L # VERSION PROTOCOL TITLE EFFECTIVE DATE 
MYL -1501D-3003 2.0 An Open -label,  Rand omized,  Multi -center,  
Parallel -Group  Clinical Trial Comparing  the 
Efficacy  and Safety of Mylan’s  Insulin  Glargine  
with Lantu s® in Type 1 Diabet es Mellit us 
Patien ts-An Extensi on Study. 06-May-2016 
I agree: 
 To assume responsibility for the proper conduct of the study at this site. 
 To conduct the study in compliance with this protocol, any future amendments, and with any 
other study conduct procedures provided by Quintiles and Mylan. 
 Not to implement any changes to the protocol without agreement from the Sponsor and 
prior review and written approval from the Competent Authority and/or Independent  Ethics 
Committee (IEC)/Institutional Review Board (IRB), as applicable, except where necessary 
to eliminate an immediate hazard to the patients. 
 That I am thoroughly familiar with the appropriate use of the investigational product(s) as 
described in this protocol, and any other information provided by the Sponsor, including 
but not limited to the following: the current Investigator’s Brochure (IB) or equivalent 
document. 
 That I w ill comply with the revised Declaration of Helsinki (2013), the International 
Conference on Harmonisation Guidelines on Good Clinical Practice (ICH-GCP), and other 
applicable regulations and guidelines for the conduct of clinical trials. 
 To ensure that all persons assisting me with the study are adequately informed about the 
investigational product(s) and of their study-related duties and functions as described in the 
protocol. 
 That I have been informed that certain regulatory authorities require the Sponsor to obtain 
and supply, as necessary, details about each Investigator’s proprietary interest in the Sponsor 
or the investigational product, and, more generally, about each Investigator’s financial ties with 
the Sponsor. Mylan will use and disclose the information solely to comply with regulatory 
requirements. Hence, I agree: 
• To supply Mylan with any necessary information regarding proprietary interest and 
financial ties (including those of my spouse and dependent children); 
• To promptly update this information if any relevant changes occur during the course 
of the study and for 1 year following completion of the study; and 
• That Mylan may disclose to regulatory authorities any information it has about such 
proprietary interests and financial ties. 
 
Investigator’s Signature Date 
 
Name and Title of Investigator (typed or printed) 